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ABSTRACT 
Introduction 
Acute heart failure (AHF) is the most common primary diagnosis for hospitalized heart disease 
cases in Africa. Increased fatty acid oxidation (FAO) with heart failure (HF) triggers detrimental 
effects on the myocardium, we hypothesized that diabetic rat hearts subjected to AHF display 
lower cardiac function vs. controls and that Trimetazidine (TMZ) (a partial FAO inhibitor) 
counters this effect. 
Aims 
1) To establish an ex vivo AHF model for diabetic hearts; 2) Assess whether TMZ treatment
offers cardioprotection to diabetic rat hearts subjected to an AHF protocol; and 3) Delineate 
underlying mechanisms by evaluating markers for oxidative stress, mitochondrial uncoupling, 
apoptosis and metabolic dysregulation. 
Methods 
Vehicle control male Wistar rats were injected with citrate buffer. To induce diabetes rats were 
administered streptozotocin (60 mg/kg) for one week vs. non-diabetic controls. Hearts were 
perfused on the Langendorff retrograde perfusion system for three phases: Stabilization - (11 
mM glucose- non-diabetic, and 30 mM glucose- diabetic hearts) at 100 cm H2O (30 min); AHF – 
(1.5 mM palmitic acid, 2.5 mM glucose) at 20 cm H2O (35 min); and Recovery– (1.5 mM 
palmitic acid, 11 mM glucose or 30 mM glucose) at 100 cm H2O (30 min). 1 µM TMZ was 
administered at the start of recovery. In addition, we evaluated necrosis and infarct size by 
tetrazolium (TTC) staining at the end of the AHF phase. Western blotting was performed for 
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markers of apoptosis (pBAD/BAD), oxidative stress (superoxide dismutase 2 [SOD2], 
conjugated dienes [CDs], thiobarbituric acid reactive substances (TBARS), reduced/oxidized 
glutathione [GSH/GSSG] analysis, oxygen radical absorbance capacity [ORAC]), mitochondrial 
uncoupling (uncoupling protein 2 [UCP2]) and metabolic dysregulation (advanced glycation end 
product [AGE] and polyol pathway analyses). We investigated direct effects of TMZ (1 µM) in 
H9c2 cardiomyoblasts exposed to 500 µM palmitate for 21 hours and assessed the effects of 
TMZ treatment on fatty acid-induced oxidative stress and apoptosis.  
Results 
Reduced function was seen for all groups in recovery vs. controls, while AHF-diabetic showed 
worse outcomes vs. AHF alone. TMZ treatment resulted in a robust increase in left ventricular 
developed pressure (LVDP) for diabetic hearts vs. controls. Infarct size assessment showed no 
differences. TMZ treated diabetic hearts also displayed lower AGE and higher polyol pathway 
activation vs. respective controls.  However, several markers of the AGE pathway did not show 
any significant differences for any groups. Non-diabetic and diabetic hearts displayed increased 
oxidative stress (TBARS) compared to their counterparts. TMZ treatment resulted in              
anti-apoptotic effects in hearts subjected to AHF.  TMZ exhibited antioxidant effects by lowering 
fatty acid-induced mitochondrial oxidative stress in cells.  
Conclusion 
This study successfully established a novel ex vivo model of AHF for the diabetic rat heart, and 
TMZ treatment resulted in cardioprotection for diabetic hearts. Our data suggest that TMZ may 
mediate some of its cardioprotective effects by acting as an anti-oxidant to lower myocardial 
oxidative stress triggered during AHF.  The findings also indicate that TMZ treatment may lower 
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the formation of damaging AGEs in the diabetic heart.  TMZ therefore, emerges as a putative 
therapeutic target to be considered as sole and/or combined treatment (with more conventional 
drugs) for AHF patients. 
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OPSOMMING 
Inleiding 
Akute hartversaking (AHV) is die mees algemene primêre diagnose vir gehospitaliseerde 
hartsiekte gevalle in Afrika. Verhoogde vetsuuroksidasie (VSO) met hartversaking (HV) 
veroorsaak skadelike effekte op die miokardium. Ons hipotiseer dat diabetiese rotharte 
blootgestel aan AHV verlaagde hartfunksie vertoon vs. kontroles en dat Trimetazidien (TMZ) (‘n 
gedeeltelike VSO inhibitor), hierdie effek teenwerk.  
Doelwitte 
1) Om ‘n ex vivo AHV model vir diabetiese harte te vestig; 2) Assesseer of TMZ behandeling 
kardiobeskerming verleen aan diabetiese rotharte blootgestel aan ‘n AHV protokol; en 3) 
Karakterisering van onderliggende meganismes deur merkers vir oksidatiewe stres, 
mitochondriese ontkoppeling, apoptose en metaboliese wanregulering te ondersoek. 
Metodes 
Draer kontrole Wistar rot mannetjies was met sitraat buffer ingespuit. Om diabetes te induseer 
was rotte met streptozotosien (60 mg/kg) vir een week toegedien vs. nie-diabetiese kontroles. 
Harte is geperfuseer op die Langendorff retrograad perfusie sisteem vir drie fases: Stabilisasie – 
(11 mM glukose-nie-diabeties, en 30 mM glukose-diabetiese harte) teen 100 cm H2O (30 min); 
AHV – (1.5 mM palmitiensuur, 2.5 mM glukose) teen 20 cm H2O (35 min); en Herstel – (1.5 
mM palmitiensuur, 11 mM glukose of 30 mM glukose) teen 100 cm H2O (30 min). 1 µM TMZ 
is aan die begin van herstel toegedien. Ons het addisioneel nekrose en infarktgrootte aan die 
einde van die AHV fase geevalueer met tetrazolium (TTC) kleuring. Western klad-analise is 
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uitgevoer vir merkers van apoptose (pBAD/BAD), oksidatiewe stres (superoksieddismutase 2 
[SOD2], gekonjugeerde diëne [CDs], tiobarbituursuur reaktiewe stowwe (TBARS), 
gereduseerde/geoksideerde glutatioon [GSH/GSSG] analise, suurstof radikaal absorbansie 
kapasiteit [ORAC]), mitochondriese ontkoppeling (ontkoppelingproteïen 2 [UCP2]) en 
metaboliese wanregulering (gevorderde glukasie eindproduk [AGE] en poliolpad analise). Ons 
het die direkte effek van TMZ (1 µM) in H9c2 kardiomioblaste, blootgestel aan 500 µM 
palmitaat vir 21 ure, ondersoek en die effek van TMZ behandeling op vetsuur-geïnduseerde 
oksidatiewe stres en apoptose, geassesseer.  
Resultate 
Verminderde funksie is waargeneem vir alle groepe in herstel vs. kontrole, terwyl AHV-diabete 
slegter uitkomste getoon het vs. slegs AHV. TMZ behandeling het gelei tot ‘n sterk toename in 
linker ventrikulêre ontwikkelde druk (LVDP) vir diabetiese harte vs. kontroles. Infarktgrootte 
assessering het geen verskille getoon nie. TMZ behandelde diabetiese harte het ook laer AGE en 
hoër poliolpad aktivering vs. onderskeidelike kontroles, getoon.  ‘n Aantal merkers van die AGE 
pad het egter nie betekenisvolle verskille vir enige groepe gedemonstreer nie. Nie-diabetiese en 
diabetiese harte het verhoogde oksidatiewe stres (TBARS) in vergelyking met hul ekwivalente 
getoon. TMZ behandeling het anti-apoptotiese effekte teweeggebring in harte blootgestel aan 
AHV.  TMZ het anti-oksidant effekte getoon deur die verlaging van vetsuur-geïnduseerde 
mitochondriese oksidatiewe stres in selle.  
Gevolgtrekking 
Hierdie studie het suksesvol ‘n nuwe ex vivo model vir AHV vir die diabetiese rothart gevestig, 
en TMZ behandeling het gelei tot kardiobeskerming vir diabetiese harte. Ons data stel voor dat 
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TMZ die kardiobeskermende effekte daarvan medieer deur op te tree as anti-oksidant om 
miokardiale oksidatiewe stres veroorsaak tydens AHV, te verlaag.  Die bevindinge dui ook aan 
dat TMZ behandeling die vorming van skadelike AGE in die diabetiese hart mag verlaag.  TMZ 
verskyn dus as ‘n putatiewe terapeutiese teiken om in ag te neem as enkel en/of gekombineerde 
behandeling (met meer konvensionele geneesmiddels) vir AHV pasiënte. 
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 CHAPTER 1 1
1.1 Prelude 
According to the European Society of Cardiology (ESC) acute heart failure (AHF) can be 
defined as the “rapid changes in signs and symptoms of heart failure (HF)” 
(McMurray et al., 2013). AHF is the major cause of mortality and loss of quality of life 
according to the guidelines described by international heart associations such as the ESC and the 
American Heart Association. It is a life-threatening syndrome that results in the urgent need for 
therapy (McMurray et al., 2013). Management of AHF is difficult as it does not have an 
universally accepted definition, nor is the pathophysiology properly understood (Nieminen, 
2005). A reason for this situation is the lack of focused research that subsequently limits the 
foundation of rational treatment strategies (Nieminen, 2005). AHF affects individuals in all age 
groups and is a major reason for re-hospitalization and post discharge mortality rates. Most AHF 
occurs over existing chronic HF and also within the context of diabetes. It is also the most 
common primary diagnosis in patients admitted for heart diseases in Africa (Sliwa and Mayosi, 
2013). It is therefore essential to develop/study therapeutic agents and the metabolic pathways 
involved as this will help alleviate the growing global burden of HF.   
As the focus of this study is on metabolic modulation as a therapy for AHF, it is important to 
note that high circulating levels of free fatty acids (FFAs) can elicit damaging effects on 
myocardial function by “oxygen wastage” and diminished mitochondrial adenosine triphosphate 
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(ATP) generation (Essop and Opie, 2004).  By contrast, glucose is proposed to be beneficial to 
the failing heart and here drugs like trimetazidine (TMZ) - shifts metabolism from fatty acid 
(FA) oxidation to glucose metabolism - showed promising results (Quinlan et al., 2008).  
Moreover, glucose-insulin-potassium administration (GIK) can also trigger this metabolic switch 
with resultant cardioprotection (Kloner and Nesto, 2008). However, despite such progress there 
is a limited understanding of the role of metabolic fuel selection (FFAs versus glucose) within 
the context of AHF. Of note, diabetic individuals exhibit an increased risk for developing 
cardiovascular complications and it is therefore considered as one of the leading causes of 
diabetes-related morbidity and mortality (Kengne et al., 2010) The current study therefore 
investigated this research question as an increased understanding may result in the utilization of 
novel metabolic therapies for AHF. Here we hypothesized that the metabolic agent TMZ aids the 
recovery of diabetic hearts after an episode of AHF by shifting substrate utilization away from 
FA. We initially set out to establish an ex vivo rat AHF model in the diabetic heart 
(developmental component of this study) and thereafter evaluated the efficacy of TMZ within 
this context. Heart tissues were also collected and various molecular analyses performed to 
delineate underlying mechanisms driving the onset of AHF in diabetic versus non-diabetic 
hearts. Here our rationale was that an improved understanding of mechanisms involved in AHF 
± TMZ treatment may eventually lead to improved care and well-being of patients within the 
clinical setting.  
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 CHAPTER 2 2
Cardiac metabolism under physiological conditions 
2.1 Substrate utilization 
The cardiovascular system requires a continuous supply of oxygen and energy providing 
substrates to sustain rhythmic contractions (Taegtmeyer et al., 1980). When the homeostatic 
balance is disturbed in response to severe lack of oxygen this leads to cardiac damage and 
maladaptive responses (Essop, 2007). ATP is the main energy currency in the heart with a 
turnover of 6 to 8 times per minute (Lopaschuk and Ussher, 2010). To meet its energetic 
demands, the heart utilizes various energy substrates namely FFAs, glucose, lactate, ketone 
bodies and pyruvate (Lopaschuk and Ussher, 2010). The efficiency of ATP production is 
dependent on the energy substrate used, where FFAs are a major energy source for the 
mammalian adult heart, contributing approximately 60 – 80% of the energy requirements. Under 
physiological conditions approximately 95% of ATP formation in the myocardium is derived 
from oxidative phosphorylation in mitochondria, while the remainder is generated from 
glycolysis and guanidine triphosphate (GTP) formation in the citric acid cycle (Stanley et al., 
2005).  
Myocardial ATP content is moderate under physiological conditions where ATP hydrolysis has a 
turnover approximately every 10 seconds (Opie, 1991). ATP is broken down at a high rate, and 
re-synthesized by utilizing energy from FAs, glucose and lactate in the mitochondrion (Stanley, 
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2001). An average of 60 – 70% of ATP hydrolysis is utilized for contractile shortening, with the 
remainder mainly employed for the sarcoplasmic reticulum and ionic modulators such as the 
Ca
2+
 pump (Figure 2.1). Energy required for mitochondrial oxidative phosphorylation derives 
from electrons that are transferred from carbon fuels (FAs, glucose and lactate) by 
dehydrogenation reactions that produce reducing equivalents, i.e. nicotinamide adenine 
dinucleotide reduced (NADH) and flavin adenine dinucleotide reduced (FADH2) (Figure 2.1) 
(reviewed in Stanley et al., 2005). FA β-oxidation and the citric acid cycle are primary 
contributors to electrons utilized in mitochondrial oxidative phosphorylation, with pyruvate 
dehydrogenase (PDH) and glycolysis contributing to a lesser extent (Stanley et al., 2005).  
 
 
Figure 2.1. Myocardial substrate utilization: Metabolic fuel substrates are converted to reducing equivalents 
NADH and FADH2 to produce mitochondrial ATP that is utilized for optimal cardiac function.                       
NADH: nicotinamide adenine dinucleotide reduced; FADH2: flavin adenine dinucleotide reduced; ATP: adenosine 
triphosphate; SR: sarcoplasmic reticulum. 
The majority of the ATP produced requires O2 for mitochondrial oxidative metabolism and the 
efficiency of this reaction is dependent on the type of substrate used (Weiss and Maslov, 2004). 
For example, one molecule of glucose can produce 31 ATP molecules through glycolysis and 
glucose oxidation and this requires 6 O2.  However, the production of 105 ATP molecules by 
palmitate oxidation requires 23 O2 – FAs therefore need more O2 per molecule ATP generated. 
Fatty acids 
Glucose  
Lactate 
NADH 
FADH
2
 ATP 
Contractile function 
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Thus FAs are a less efficient energy substrate under stressful conditions, e.g. the failing or 
ischemic heart (Lopaschuk and Ussher, 2010).  
2.2  Regulation of glucose uptake     
Glucose is one of the major fuel substrates that contribute to myocardial metabolism. Glycolytic 
substrates are derived by dietary intake and/or exogenous glucose and endogenous (glycogen) 
stores (Stanley et al., 2005). Moreover, during the fed state it becomes the primary energy 
substrate by intake of dietary carbohydrates. Various triggers may stimulate glycogenolysis e.g. 
ischemia, adrenergic stimulation, reduced myocardial ATP levels and intense exercise (Goldfarb 
et al., 1986; Hue and Taegtmeyer, 2009; Stanley et al., 1997a).  
Myocardial glucose transport is dependent on plasma glucose concentrations and the availability 
of glucose transporters (GLUT) within the plasma membrane (Santalucia, 1999). Two main 
glucose transporters have thus been identified in the heart, i.e. GLUT1 and GLUT4 (Doria-
Medina et al., 1993; James et al., 1989). GLUT1 and GLUT4 are the predominant glucose 
transporters in the fetal and adult heart, respectively (Postic et al., 1994; Santalucía et al., 1992). 
Although GLUT1 is the predominant fetal transporter, it can also contribute to constitutive 
glucose uptake in the adult heart. However, GLUT4 facilitates the majority of basal glucose 
uptake in the adult heart (Bergman et al., 1980; Bersin and Stacpoole, 1997). Insulin availability 
leads to the translocation of GLUT1 and GLUT4 from intracellular locations to the plasma 
membrane to thereby increase glucose uptake by the heart (Russell et al., 1999; Young et al., 
1997). GLUT1 is more profound in the intracellular pool under conditions that favor basal 
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cardiac glucose uptake (Luiken et al., 2004), while GLUT4 is the insulin-responsive transporter 
(Laybutt et al., 1997; Olson and Pessin, 1996). Glucose transporters can be stimulated in 
response to ischemia and/or increased work demand by the myocardium (Stanley et al., 1997a; 
Young et al., 2000, 1997).  Moreover, other regulators can also impact on the role of glucose 
transporters, e.g. increased availability of citrate and malate can inhibit its translocation and 
subsequent glucose uptake (Beauloye et al., 2002).  
2.3 Glycolysis 
Glycolysis is a cytosolic process where glucose is converted to lactate under anaerobic 
conditions, or to pyruvate under aerobic conditions. The initial step is the uptake of glucose by 
the cardiac myocyte whereafter it is rapidly phosphorylated to glucose-6-phosphate (G-6-P) by 
hexokinase II enzyme (Figure 2.2), forming a carbon skeleton of glucose impermeable to cell 
membrane. For the fetal heart GLUT1 (Postic et al., 1994; Santalucía et al., 1992) and 
hexokinase I are predominant,  however, following birth expression of these modulators decrease 
while GLUT 4 and hexokinase II are upregulated (Postic et al., 1994; Santalucía et al., 1992).  
G-6-P can either be converted to glycogen or enter the glycolytic pathway. For the latter process, 
isomerase converts G-6-P to fructose-6-phosphate (F-6-P), followed by phosphofructokinase-1 
(PFK1) leading to fructose-1,6-bisphosphate (F-1,6-BP) formation (Jaswal et al., 2011) with 
utilization of one ATP molecule (Hue and Rider, 1987). This is the rate-limiting enzyme of the 
glycolytic pathway (Depre et al., 1993; Rider et al., 2004). PFK1 may be inhibited by low pH, 
high intracellular citrate or ATP levels - stimulated by adenosine diphosphate (ADP), adenosine 
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monophosphate (AMP), phosphatase and fructose 2,6-bisphosphate (F-2,6-BP) (Depre et al., 
1993; Rider et al., 2004; Stanley et al., 2005).   
When glycolysis is coupled to glucose oxidation, pyruvate is translocated into the mitochondrion 
by the mitochondrial pyruvate carrier (MPC). PDH subsequently converts pyruvate to         
acetyl-CoA that enters the citric acid cycle, leading to the production of 31 ATP molecules per 
glucose molecule (Herzig et al., 2012; Panchal et al., 2001, 2000). However, if pyruvate does not 
undergo further oxidation (anaerobic conditions) then it is converted to lactate by lactate 
dehydrogenase. The latter step is crucial as it enables the conversion of NADH back to oxidized 
nicotinamide dinucleotide (NAD
+
) allowing glycolysis to proceed. Phosphofructokinase-2 
(PFK2) catalyzes the conversion of F-1,6-BP to F-2,6-BP (Hue and Rider, 1987). PFK2 can be 
inhibited by citrate and subsequently increase F-2,6-BP levels to ultimately inhibit PFK1 activity 
(Kantor et al., 2001). PFK2 activity can also be stimulated by protein kinase C (PKC) and 
phosphatidylinositol 3-kinase (PI3K)  (An and Rodrigues, 2006; Depre et al., 1998; Marsin et 
al., 2000).  
The next step in the glycolytic pathway is the conversion of F-1,6-BP by aldolase into triose 
phosphates, i.e. dihydroxylacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G-3-P). 
In addition, the rate-limiting enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
catalyzes the conversion of G-3-P to 1,3-diphosphoglycerate producing glycolytically-derived 
NADH (Ceriello et al., 2002). This is an important step during conditions such as ischemia 
(Stanley et al., 2005). The accumulation of cytosolic NADH also leads to the inhibition of 
GAPDH activity while upregulation of NAD
+
 activates GAPDH activity (Stanley et al., 2005). 
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Increased lactate concentrations can also lead to the inhibition of NADH to NAD
+
 conversion 
and therefore in a reduction of GAPDH activity. Subsequent to this step, phosphoglycerokinase 
transfers a phosphate between 1,3-bisphosphoglycerate (1,3-BPG) to ADP to form ATP and 
glycolytic flux thus yields two ATP molecules per glucose metabolized. During aerobic 
conditions glycolysis typically contributes approximately 10% towards ATP production  (Opie 
and Knuuti, 2009).  
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Figure 2.2. Regulation of the glycolytic pathway: Glucose is metabolized to pyruvate through several steps. 
GAPDH and PFK1 are stimulated in response to various stimuli. AMPK: adenosine monophosphate activated 
kinase; 1,3-BPG: 1,3-bisphosphoglycerate; DHAP: dihidroxylacetone phosphate; F-6-P: fructose-6-phosphate;        
F-1,6-BP: fructose 1,6-bisphosphate; F-2,6-BP: fructose 2,6 bisphosphate; G-6-P: glucose-6-phosphate;                  
G-3-P: glyceraldehyde-3-phosphate; LDH: lactate dehydrogenase; PFK1: phosphofructokinase 1; PFK2: 
phosphofructokinase 2; PDH: pyruvate dehydrogenase; PKC: protein kinase C; PKA: protein kinase A; PI3K: 
phosphoinositide-3-kinase; TIM: triose phosphate isomerase. 
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Glycolytic end-products formed (NADH, pyruvate) can be transported into the mitochondrial 
matrix and utilized for energy production by oxidative metabolic processes. However, when 
oxygen availability is limited (e.g. during ischemia) pyruvate is converted to lactate by lactate 
dehydrogenase and subsequently this leads to the oxidation of NADH to NAD
+
. Lactate is taken 
up into the myocardium via monocarboxylic acid transporter 1 (MCT-1) (Garcia et al., 2015; 
Johannsson et al., 1997). An impairment in pyruvate oxidation and increased glycolysis can lead 
to increased lactate production during disease states such as diabetes (Avogaro et al., 1990; Hall 
et al., 1996; Stanley et al., 1997b) or ischemia (Depre et al., 1998; Opie, 1991; Stanley et al., 
1997a). Pyruvate formed by glycolysis can either be converted to lactate, decarboxylated to 
acetyl-CoA or carboxylated to oxaloacetate or malate (Randle, 1986). Pyruvate decarboxylation 
is the major irreversible step in the oxidation of carbohydrates and it is catalyzed by PDH 
(Randle, 1986). PDH forms part of a complex that consists of pyruvate dehydrogenase kinase 
(PDK) and pyruvate dehydrogenase phosphatase (PDP). Here PDK can inhibit PDH through 
phosphorylation and can alleviate the inhibition by the process of de-phosphorylation (Reviewed 
in Stanley et al., 2005). PDH is inhibited by pyruvate dehydrogenase kinase 4 (PDK4) mediated 
phosphorylation on the E1 subunit of the enzyme complex (Randle and Priestman, 1996). PDK4 
is the major isoform that is induced in response to starvation, diabetes and peroxisome 
proliferator activated receptor-α (PPAR-α) (Bowker-Kinley et al., 1998; Harris et al., 2001). 
Elevated circulating lipids and the accumulation of intracellular long-chain FAs (e.g. with fasting 
or diabetes) lead to increased PPAR-α mediated expression of PDK4. The latter results in 
increased PDH inhibition and a decrease in pyruvate derived from glycolysis and lactate 
oxidation (Harris et al., 2001). Pyruvate can also inhibit PDK by lowering acetyl-CoA, free CoA 
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and NADH/NAD
+
 ratios (Kerbey et al., 1976; Randle and Priestman, 1996; Whitehouse et al., 
1974). The PDH complex also contains a PDH phosphatase that can be increased in response to 
Ca
2+
 and Mg
2+
 (McCormack and Denton, 1984. This provides a mechanism for adrenergic 
stimulation’s effects on PDH, i.e. it increases cytosolic and mitochondrial Ca2+ to activate PDH 
(McCormack and Denton, 1989). Lastly, increased FFA supply and FA oxidation inhibit PDH 
activity and pyruvate oxidation (Randle, 1986).  
2.4 Fatty acid uptake and metabolism 
FAs are the preferred fuel substrate and accounts for approximately 70% of ATP production 
under basal conditions (Merkel, 2002). The amount of FAs utilized by the heart is dependent on 
both the source and the presence of competing energy substrates together with the heart’s 
metabolic demand and the contributions/activities of the citric acid cycle and electron transport 
chain (ETC) (Lopaschuk and Ussher, 2010). The degree of FA uptake is dependent on the 
concentration of non-esterified FAs present in plasma (Bing et al., 1954; Lopaschuk et al., 1994; 
Wisneski et al., 1985). Here FAs are transported in plasma being bound to albumin or covalently 
attached in triglycerides and enclosed with chylomicrons or very low density lipoproteins 
(Lopaschuk et al., 1994).  During the fasted state (low insulin, high catecholamines) the systemic 
FA concentration increases thereby leading to elevated rates of FA uptake (Lopaschuk et al., 
1994).  For example, plasma FFA concentration can increase to 1 mM in the event of metabolic 
stress situations such as ischemia and diabetes (Lopaschuk et al., 1994).  
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FAs are taken up into the cardiomyocyte by passive diffusion or protein-mediated transport 
across the sarcolemma (van der Vusse et al., 2000) by fatty acid translocase (FAT) and plasma 
membrane fatty acid binding protein (FABPm) (Glatz et al., 2001) (Figure 2.3). The 
predominant FAT protein is known as CD36 and it is also the main FA uptake regulator found in 
the heart and skeletal muscle (Schaffer, 2002; van der Vusse et al., 2000). Of note, individuals 
with mutations in CD36 are associated with decreased long-chain FA analog uptake suggesting 
that CD36 is closely linked to the regulation of myocardial FA uptake (Schaffer, 2002). Once 
transported FAs bind to FABPm they are converted by fatty acyl-CoA synthetase (FACS) 
(Schaffer, 2002). This is followed by the addition of a CoA group to the FA by fatty acyl-CoA 
synthetase that enables long-chain FAs to enter the mitochondrion (Lopaschuk and Ussher, 
2010). After uptake and esterification fatty acyl-CoA can be utilized to produce ATP for the 
triglyceride or the intracellular lipid pools.  FABP and FACS associated to CD36 can also be 
found within the cytoplasm and converts intracellular FFA to fatty acyl-CoA (Schaffer, 2002).  
FA β-oxidation mainly occurs in mitochondria and to a lesser extent in peroxisomes (Kunau et 
al., 1995; Schulz, 1994) and primarily leads to the production of NADH, FADH2 and acetyl-
CoA. Long-chain fatty acyl-CoA can be esterified by glycerolphosphate acyltransferase to 
triglyceride or by acylcamitine palmitoyltransferase I (CPT-I) to long-chain fatty acylcamitine in 
the intermembrane space (Lopaschuk et al., 1994).   
Long-chain fatty-acyl carnitine is transported across the mitochondrial inner membrane by 
carnitine translocase and then converted back into long-chain fatty acyl-CoA to subsequently 
enter the FA β-oxidation spiral (Lopaschuk et al., 1994). Acetyl-CoA, NADH and FADH2 are 
Stellenbosch University  https://scholar.sun.ac.za
 13 
 
produced after each FA oxidation cycle and reducing equivalents are employed by the 
mitochondrial ETC for ATP generation.  
The inner mitochondrial membrane is impermeable to long-chain acyl-CoA and it is therefore 
transferred from the cytosol into the matrix by the carnitine-dependent transport system (Kerner 
and Hoppel, 2000; Lopaschuk et al., 1994). The formation of long-chain acylcarnitine from long-
chain acyl-CoA is catalyzed by CPT-I between the inner and outer mitochondrial membrane. 
CPT-I is the predominant in the regulation of mitochondrial FA uptake (Kerner and Hoppel, 
2000; Lopaschuk et al., 1994).  The long-chain acylcarnitine is subsequently transported across 
the inner mitochondrial membrane by carnitine acyltranslocase. Various factors influence the 
regulation of FA oxidation and here especially malonyl-CoA and the glucose-FA cycle play key 
roles.  Malonyl-CoA is a potent inhibitor of CPT-I and hence mitochondrial FA uptake and 
oxidation (McGarry et al., 1978, 1977; Paulson et al., 1984). Here malonyl-CoA decarboxylase 
(MCD) and acetyl-CoA carboxylase (ACC) primarily regulate malonyl-CoA levels as MCD 
converts malonyl-CoA to acetyl-CoA while ACC catalyzes the reverse reaction.  MCD inhibition 
would thus potentially reduce CPT-I activity and in parallel attenuate FA oxidation while ACC 
inhibition would release the brake on CPT-I activity and increase FA oxidation (Dyck, 2004; 
Kolwicz et al., 2012; Ussher et al., 2012).  Carnitine acyl translocase (CAT) transports 
acylcarnitine across the mitochondrial intermembrane and this leads to free carnitine. Fatty acyl-
CoA is restored by carnitine palmitoyl transferase-II (CPT-II) which is then transported back into 
the intermembrane space by CAT (Kerner and Hoppel, 2000; Lopaschuk et al., 1994; Schulz, 
1994). Once fatty acyl-CoA enters the mitochondrial lumen it undergoes FA β-oxidation. 
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The metabolism of long-chain CoA inside the mitochondrial matrix involves the metabolism of     
acyl-CoA by a) acyl-CoA dehydrogenase, b) enoyl-CoA hydratase, c) L-3-hydroxyacyl-CoA 
dehydrogenase and d) 3-ketoacyl-CoA thiolase (3-KAT) (Schulz, 2008).  These enzymes exist in 
different isoforms with varying chain lengths and shortens each fatty-acyl by two carbons and in 
the process generating acetyl-CoA, FADH2 and NADH.  Each enzyme has a feedback inhibition 
mechanism e.g. by NADH and FADH2. For example, the feedback inhibition of 3-KAT can 
occur as a result of the accumulation of acetyl-CoA.  This is vital in the event of low metabolic 
demand where decreased ETC and citric acid cycle activity leads to the accumulation of      
acetyl-CoA, FADH2 and NADH and subsequent inhibition of FA β-oxidation enzymes  
(Fillmore and Lopaschuk, 2011). Therefore flux through FA β-oxidation is dependent on both 
myocardial demand and the availability of fuel substrates (Lopaschuk et al., 2007).  
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Figure 2.3. Fatty acid metabolism: FAs enter the cell by transporter proteins that are converted to fatty acyl-CoA in the cytosol. 
CPT-I facilitates transport into the mitochondrion which is inhibited by malonyl-CoA, while CAT removes carnitine groups. 
Fatty acyl-Co-A is then utilized in the mitochondrial matrix for FA β-oxidation. ACC: acetyl-CoA carboxylase; CAT: carnitine 
acyltransferase; CPT-I: carnitine palmitoyl transferase; CoA: co-enzyme A; FAs: fatty acids; FACS: fatty acyl-CoA synthase; 
FADH2: Flavin adenine dinucleotide reduced; AT/CD36: fatty acid translocase; FABPm: fatty acid binding protein; LPL: 
lipoprotein lipase; MCD: malonyl-CoA decarboxylase; NADH: nicotinamide adenine dinucleotide reduced.  
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2.5 Mitochondrial energetics 
Mitochondria are often referred to as the “powerhouse” of the cell as they are the major sites of 
ATP production. They have tightly regulated and active pathways that facilitate the conversion 
of fuel substrates into electrons and finally into ATP.  Mitochondria possess its own genome that 
provides regulatory proteins and enzymes required to operate efficiently. The myocardium is 
enriched with mitochondria in order to maintain ATP levels and they typically occupy 
approximately 25 – 35% of the total myocardial volume (Dobson and Himmelreich, 2002). 
Mitochondria are divided into two populations, i.e. intramyofibrillar and sarcolemmal (Palmer, 
1977) and such sub-populations can be distinguished by differences in terms of cristae structure, 
respiration rates and the expression of distinct metabolic proteins (Palmer, 1977; Roden et al., 
1996). However, both populations contribute towards optimal cardiac functioning by ATP 
generation and maintenance of ionic balance (Ishiki and Klip, 2005).  
2.6 The citric acid cycle 
The citric acid cycle also known as the Krebs or tricarboxylic acid cycle is a primary point of 
myocardial metabolism (Owen et al., 2002). Acetyl-CoA - originating from the oxidation of 
carbohydrates, FAs and proteins - fuels the citric acid cycle (Gibala et al., 2000; Neely et al., 
1972).  This is a crucial process as depletion of the citric acid cycle within the myocardium leads 
to a decline in contractile function.  However, this can be reversed by the addition of anaplerotic 
substrates such as malate, 2-oxoglutarate, succinyl-CoA, oxaloacetate and fumarate (Gibala et 
al., 2000; Russell and Taegtmeyer, 1991; Taegtmeyer et al., 1980). The citric acid cycle enzymes 
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are located within the mitochondrial matrix, with succinate dehydrogenase found within the 
inner mitochondrial membrane (Humphries and Szweda, 1998; Kerner and Hoppel, 2000).  This 
cycle also generates reducing equivalents for ATP generation, e.g. α-ketoglutarate catalyzes the 
conversion of α-ketoglutarate to succinyl-CoA and produces NADH and CO2 (Cooney et al., 
1981, Humphries & Szwelda, 1998; Moreno-Sanchez et al., 1990). Reducing equivalents 
generated by the citric acid cycle can then feed into the mitochondrial ETC for ATP generation 
(Gibala et al., 2000). 
2.7 The electron transport chain and oxidative phosphorylation 
The ETC is composed of five enzymes complexes (I – IV) and V (ATPase synthase) situated 
within the inner mitochondrial membrane. The adenosine nucleotide translocase functions by 
transporting ATP to the cytoplasm in exchange for ADP; this collectively referred to as the 
oxidative phosphorylation system (Casademont and Miro, 2002). Electrons enter the ETC 
through NADH:ubiquinone oxidoreductase (complex I), a large complex that consists of 
approximately 45 subunits (Carroll, 2005, 2002; Cecchini, 2003). Complex I functions by 
transferring electrons from NADH to ubiquinol through various redox centers such as flavin 
mononucleotide moiety and clusters of seven to nine iron-sulfur and up to three ubisemiquinone 
species (Friedrich & Scheide, 2000; Koopman et al., 2005; Ohnishi, 1998; Yano et al., 2000). 
Energy is preserved in this complex where four protons are transported across the mitochondrial 
inner membrane coupled to electron transfer; therefore conserving energy. Moreover, complex I 
contributes towards the proton-motive force and in turn supports ATP synthesis while 
maintaining the NAD
+
/NADH ratio within the mitochondrial matrix and providing ubiquinol to 
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complex III (Hirst, 2005). A phospholipid cardiolipin may also play a crucial role in the optimal 
functioning of complex I in the ETC (Dröse et al., 2002; Fry and Green, 1981; Paradies et al., 
2001; Ragan, 1978), although this exact mechanism has not been elucidated thus far.   
Complex II, also known as succinate dehydrogenase or succinate:ubiquinone oxidreductase plays 
a crucial role by coupling the oxidation of succinate to fumarate and subsequently reducing 
ubiquinone (Cecchini, 2003; Yankovskaya et al., 2003). Complex III (cytochrome bc1 complex) 
oxidizes the ubiquinol generated by complexes I and II and here electrons are transferred from 
ubiquinol to cytochrome c rendering the proton motive Q cycle (Cecchini, 2003). Complex I and 
II transfer electrons through cytochrome c to the Q cycle through to complex IV (di Rago et al., 
1990).  
An energy carrier between complexes II and IV is known as cytochrome c (Gupte and 
Hackenbrock, 1988). Complex IV  (also known as cytochrome oxidase) generates a proton 
gradient that reduces oxygen to water (Belevich et al., 2006; Cecchini, 2003; Gupte and 
Hackenbrock, 1988; Ludwig et al., 2001; Yoshikawa, 2003; Yoshikawa et al., 2006). Complex V 
(also known as ATPase or F1F0) is the final step in the mitochondrial ETC and here ATP is 
produced by pumping protons by the electromagnetic gradient (Cecchini, 2003).  
2.8 The Randle cycle: The link between glucose and fatty acid metabolism 
The process whereby FAs and glucose regulate each other is referred to as the ‘’Randle cycle’’ 
(Koonen et al., 2005) and was first described by Randle and colleagues during the 1960s 
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(Garland et al., 1963; Randle et al., 1964).  The preferential utilization of fuel substrates (glucose 
versus FAs) is regulated by interlinked mechanisms and here the regulation of PDH plays an 
important role. The rate-limiting step of pyruvate decarboxylation is an irreversible step 
catalyzed by PDH (Patel and Korotchkina, 2006; Randle, 1986). PDH can be inhibited by 
phosphorylation on the E1 subunit on the enzyme complex by PDK and be activated by de-
phosphorylation via a PDH phosphatase. However, higher FA β-oxidation leads to increased 
acetyl-CoA/CoA and NADH/NAD
+
 ratios that results in decreased myocardial PDH activity 
(Clarke, 1996; Higgins et al., 1981; Kruszynska et al., 1991; Lopaschuk et al., 1994; Stanley et 
al., 1997a). Here such byproducts activate PDK which results in the inhibition of PDH. Such 
changes are also proposed to lead to increased cytosolic citrate levels that in turn can inhibit 
PFK1 and PFK2 and lower glycolysis (Hue and Taegtmeyer, 2009).  
As this chapter summarized the essentials of cardiac metabolism under physiological conditions, 
it provides a useful foundation to evaluate metabolic dysfunction within the context of 
cardiovascular complications. 
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 CHAPTER 3 3
The burden of cardiovascular disease 
3.1 Introduction 
Cardiovascular complications are leading causes of death and disability in the industrialized 
world (Nichols et al., 2014). Currently cardiovascular diseases (CVD) account for 31% global 
mortality rate according to the World Health Organization (WHO) 
(http://www.who.int/mediacentre/factsheets/fs317/en/) and major risk factors such as obesity and 
diabetes further exacerbate this increasing burden of disease (Dimmeler, 2011). Diabetes is 
robustly associated with CVD and here mortality rate is two to four-fold higher in such 
individuals (Gu et al., 1998).  Thus there is a tight inter-linkage between these two debilitating 
conditions and this will further increase in the next years. For example, projections indicate that 
by 2030 CVD will be the leading cause of mortality in Africa (Mensah, 2008), while the South 
African National Department of Health indicated that diabetes is a major risk factor for CVD 
development (Norman et al., 2007). Moreover, diabetic individuals who develop CVD suffer 
tremendously in comparison to  non-diabetic persons with similar conditions (MacDonald et al., 
2008). There are also other risk factors associated with CVD in sub-Saharan Africa (SSA) such 
as stroke and hypertension and here hypertension is predicted to be prevalent in approximately 
30% of adults in SSA (Dalal et al., 2011).  Such risk factors further fuel CVD development, e.g. 
the INTERHEART Africa study found that hypertension and diabetes were most common in 
black Africans suffering acute myocardial infarction (Steyn et al., 2005a).  
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3.2 Heart failure (HF) 
Heart failure (HF) was described by Hippocrates as shortness of breath and peripheral edema 
(Katz and Katz, 1962) and also as a clinical syndrome that significantly contributes to the burden 
of CVD in SSA (Cowie et al., 1997). A more precise definition for HF is given by Katz as “a 
clinical syndrome in which heart disease reduces the cardiac output, increases venous pressures 
and is accompanied by molecular abnormalities that cause progressive deterioration in the failing 
heart and premature myocardial cell death” (Katz, 2000). Clinical representations of HF are 
characterized by pulmonary congestion, dyspnea and fatigue. There are two broad HF 
classifications, i.e. chronic and acute. The chronic state gradually occurs over time while “acute” 
refers to the more rapid deterioration of heart function. Systolic dysfunction is the most 
frequently occurring form of HF (Kingue et al., 2005) as most of the literature was published 
prior to the recognition of HF with preserved ejection fraction (Adewole et al., 1996).  
The main causes of HF in the developing world are due to non-ischemic causes, i.e. hypertensive  
heart disease, valvular and myocardial damage from rheumatic fever and myocardial damage 
from infectious agents (Steyn et al., 2005b). HF tends to occur frequently at a younger age in 
SSA and this is possibly due to the significant contribution of rheumatic fever (Doust et al., 
2005). In agreement, other studies (Damasceno et al., 2007; Kingue et al., 2005; Oyoo and 
Ogola, 1999; Sliwa and Mocumbi, 2010) suggested that the primary underlying causes of  HF 
are different within the African context and thus include mediators such as endomyocardial 
fibrosis and tuberculous pericarditis.  Additional risk factors include the so-called Westernized 
lifestyle that often leads to increased hypertension, obesity and diabetes especially in urban areas 
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(Mayosi et al., 2009).  Such complexity within the SSA context may also be responsible for the 
variation of HF etiologies observed (Bloomfield et al., 2013) while sub-optimal healthcare 
systems and limited resources/research will also further fuel HF prevalence.  
3.3 Acute heart failure (AHF) 
The ESC describes AHF as “the rapid onset of, or change in, symptoms and signs of HF” 
(McMurray et al., 2012) resulting in the need for urgent therapy.  AHF can be divided into two 
sub-types namely a new onset known as de novo AHF or the acute worsening of an existing, 
chronic HF condition (Metra et al., 2010).  It is also a complex clinical syndrome and 
management of AHF is difficult as it does not have a universally accepted definition, nor is the 
pathophysiology properly understood. It also varies in it terms of underlying pathophysiology, 
clinical representations and treatments (Metra et al., 2010). AHF accounts for one of the main 
causes of hospitalization worldwide (McMurray et al., 2012). It is the most common diagnosis in 
individuals >65 years of age, with increased in-hospital mortality and an even higher post-
discharge mortality, with an increased chance of  re-admission (Metra et al., 2010).  
Treatment strategies for chronic HF have resulted in improvements in symptoms (Lindenfeld et 
al., 2010; McMurray et al., 2012). Here treatment strategies include diuretics, oxygen and 
vasodilators but fail to reduce mortality rates (Lindenfeld et al., 2010; McMurray et al., 2012). 
These symptoms occur predominantly as a consequence of severe pulmonary congestion due to 
increased left ventricular filling pressure (with or without low cardiac output). CVD such as 
coronary artery disease, hypertension, atrial arrhythmias and other conditions (e.g. diabetes) are 
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often present and may contribute to the pathophysiology of AHF (Adams et al., 2005; Cleland et 
al., 2003; Fonarow et al., 2008). Despite treatments the morbidity and mortality rates for AHF 
patients are increasing with a 30% chance of re-hospitalization and a 90 day post-discharge 
mortality rate (Gheorghiade et al., 2005). There has been relatively limited research undertaken 
on AHF in SSA although The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF) trial 
(Figure 3.1) demonstrated that such patients displayed mean age of 52 years.  Here 
approximately 46% were diagnosed with AHF as consequence of hypertension, while for 
rheumatic fever and ischemia the figures were 14.3 and 7.7%, respectively (Damasceno et al., 
2012).   
 
 
 
 
 
 
Figure 3.1 Causes of AHF in Africa in The sub-Saharan Africa Survey of Heart Failure (THESUS-HF). 
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3.4 AHF etiology 
AHF can occur with/without previous history of cardiac disease and may be related to systolic or 
diastolic dysfunction, cardiac rhythm or the incongruity between pre- and afterload (Nieminen, 
2005).  Moreover, it is the most common primary diagnosis in patients hospitalized with heart 
disease in Africa (Damasceno et al., 2012; Sliwa and Mayosi, 2013).  For hospitalized patients 
with de novo AHF, they usually present with acute pulmonary edema and cardiogenic shock 
together with hypertension and coronary syndrome (Nieminen et al., 2006). Underlying causes 
may also be of ischemic or non-ischemic origin (Drexler et al., 2012). Regardless of the cause, 
AHF patients present with systemic and pulmonary congestion as a consequence of left 
ventricular filling with/without reduced cardiac output (Gheorghiade et al., 2005). Numerous 
cardiovascular conditions such as coronary heart disease, hypertension, valvular heart disease 
and non-cardiac related conditions such as renal failure contribute towards the pathophysiology 
of AHF (Adams et al., 2005; Cleland et al., 2003; Fonarow et al., 2008).   
The etiology of HF can be divided into two subtypes, i.e. individuals with CVD history (e.g. 
myocardial ischemia, coronary artery disease) and patients without such a history (Katz, 2000). 
The early stages of HF are usually asymptomatic due to compensatory mechanisms that include 
the renin-angiotension system, sympathetic nervous system and the progression of myocardial 
hypertrophy. Such mechanisms also play a role in HF onset by advancing ventricular remodeling 
(Casademont and Miro, 2002; Goldenthal and Marín-García, 2002; Henry et al., 1981; Kelly and 
Strauss, 1994). Due to the diverse etiology of HF various pharmacotherapies are utilized for 
treatment, especially in individuals with complicated disorders like diabetes, insulin resistance 
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and obesity. HF with an ischemic origin progresses slowly post-myocardial infarction and 
subsequently affects ventricles with alterations in both infarct and non-infarct regions of the 
myocardium. Thus it is clear that AHF is a complex syndrome that is difficult to treat and hence 
requires the development of novel and effective therapies.  
3.5 Experimental models of AHF  
AHF is linked to a relatively high in-hospital mortality rate, especially in patients which have 
reduced systolic blood pressure. As summarized in the prelude in chapter 1 of this review, it is 
pivotal to find novel therapeutic strategies to counteract this effect. 
Our model of de novo AHF has been modified from an existing ex vivo model of de novo AHF 
setup by Deshpande et al. (Deshpande et al., 2010; Opie and Deshpande, 2016; Opie et al., 
2010). Their AHF model consisted of 3 phases i.e. 30’ Stabilization, 35’ AHF and 30’ Recovery. 
The model is a representation of cardiogenic shock where its perfusion pressure governs the 
external mechanical work in the rat heart which is suddenly decreased. This is similarly observed 
when contractility is reduced in the myocardium and hypotension occurs. This model also 
employs hypotension accompanied by a decreased heart rate and alterations in concentration of 
substrates (calcium, fatty acids and glucose) (Deshpande et al., 2010; Opie and Deshpande, 
2016; Opie et al., 2010). It has similarities and differences to AHF within the clinical setting that 
is typically accompanied by relatively low blood pressure (also evident in patients with 
Takotsubo cardiomyopathy) (Wittstein, 2012; Wittstein et al., 2005) and possibly accompanied 
by a reduced systolic pressure that ranges between 50 – 104 mmHg (Gheorghiade et al., 2006). 
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In Deshpande’s de novo AHF model they focused on increased adrenaline levels during the AHF 
phase and also by altering calcium, glucose and fatty acid levels (Opie et al., 2010). Of note, 
catecholamines are increased in response to high adrenaline levels and in turn leads to the 
upregulation of FA oxidation.  This model of AHF was in fact a modified version of a 
Langendorff underperfused ischemic model that was originally established by Bricknell and 
Opie (Bricknell and Opie, 1978).  The original model utilized the same perfusion pressures as 
found in Deshpande’s work.  What about ischemia in this instance?  Ischemia is defined as the 
reduction in arterial blood flow (Jennings, 1970). However, in isolated ischemic rat hearts 
perfused with oxygenated nutrients, it can be defined as when the flow of oxygenated nutrients is 
either reduced or completely cut off from the isolated heart (Sakai et al., 2016). The latter is one 
of the key factors that distinguishes Deshpande’s AHF model to a classical ischemic isolated 
heart model. 
In our AHF model we solely concentrated on the metabolic effects (supra-physiological fatty 
acids and reduced glucose) during AHF whereas Deshpande et al. (2010) focused more on 
specific molecular alternations. 
3.6 Metabolic alterations in the failing heart 
Research focusing on the expression of metabolism during HF predominantly concentrated on 
the end-stage of this condition. For example, under such circumstances there is a down-
regulation of FA oxidation enzymes and this correlates with a switch towards increased glucose 
oxidation (Stanley et al., 2005). In agreement, analysis of hearts from transplant recipients 
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showed a marked decrease in the activity of FA β-oxidation enzymes versus donor hearts (Sack 
and Kelly, 1998). Further, these hearts displayed attenuated long-chain acyl-CoA dehydrogenase 
(LCAD) and medium-chain acyl-CoA dehydrogenase (MCAD) gene expression, with no 
changes in MCAD protein expression (Karbowska et al., 2003). However, others found 
contrarian results with HF where higher FA β-oxidation and lower glucose oxidation (Murray et 
al., 2012; Opie, 2004). This probably depends on the stage of HF and the higher FA utilization 
likely occurs during the earlier stages of HF progression. Here Opie (Opie, 2004) described a 
‘’metabolic vicious cycle’’ where the lower cardiac output found with HF results in a 
compensatory hyperadrenergic state that hyperphosphorylates the sarcoplasmic reticulum to 
lower cardiac output. In parallel, supraphysiological, circulating FFA concentrations are taken up 
by the cardiomyocyte and metabolized by heart mitochondria. However, this can lead to 
uncoupling of mitochondrial respiration and result in an energy-depleted state thereby causing 
further contractile dysfunction in the failing heart. For example, Murray et al. (Murray, 
Anderson, Watson, Radda & Clarke, 2004; http://dx.doi.org/10.1016/S0140-6736(04)17402-3) 
showed that supraphysiological plasma FFA concentrations with HF manifest in parallel with 
decreased and increased levels of GLUT4 and uncoupling proteins (UCPs), respectively. 
Moreover, increased mitochondrial reactive oxygen species (ROS) (due to higher FA oxidation) 
can also activate UCPs and thereby promoting uncoupling, dissipation of membrane potential 
and eventually decreased mitochondrial ATP production (Figure 3.3) (Essop and Opie, 2004). 
Increased FA oxidation can also lead to PDH inhibition as discussed and thereby further 
exacerbate cardiac metabolic function (Figure 3.2) (Opie, 2004). Moreover, the FA-mediated 
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decrease in glycolysis leads to lower ATP availability for the sodium pump (Cross et al., 1996) 
that will fuel cardiac dysfunction.   
 
Figure 3.2. Metabolic dysfunction with heart failure. Free fatty acids (FFA), ryanodine receptor (RyR), 
sarcoplasmic reticulum (SR) (reproduced from Opie, 2004). 
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Figure 3.3. Mitochondrial dysfunction in the failing heart (reproduced from Essop and Opie, 
2004). 
This vicious metabolic cycle offers an argument favorable to a metabolic approach for the 
treatment of HF (Opie, 2004), i.e. by decreasing FA metabolism and/or enhancing glucose 
metabolism. Here approaches that can be employed include the anabolic hormone insulin that 
can interrupt this cycle by promoting glycolysis, enhance glycolytic ATP generation and also 
inhibit hormone-sensitive lipase to lower FFA release from adipose tissue (Randle et al., 1963). 
By contrast, the anti-anginal drug TMZ also offers cardioprotection as it acts as a FA utilization 
inhibitor.   
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 CHAPTER 4 4
Exploring links between diabetes and heart failure – metabolic focus 
4.1 Diabetes mellitus and hyperglycemia  
Diabetes is defined as a metabolic disorder characterized by chronic hyperglycemia accompanied 
with disturbances in carbohydrate, fat and protein metabolism as a result of impairment in the 
regulation of either insulin secretion, action or both (Alberti and Zimmet, 1998). Type 1 diabetes 
(insulin-dependent) is an autoimmune disease that occurs as a result of the selective destruction 
of β-pancreatic cells that subsequently leads to loss of insulin secretion. Type 2 diabetes (insulin 
resistance) is associated with diminished insulin function. Although diabetes types display 
different etiologies, they result in similar complications such as oxidative stress, organ failure 
and CVD complications (Alberti and Zimmet, 1998; Liu et al., 2013; Roglic et al., 2005). For 
example, diabetic individuals exhibit an increased risk for developing cardiovascular 
complications and the latter is one of the leading causes of diabetic-related morbidity and 
mortality (Kengne et al., 2010). Here the mortality rate is two to four-fold higher in individuals 
with diabetes (Gu et al., 1998) and it is also a known risk factor for HF onset. For example, the 
Framingham study demonstrated that HF incidence was 2x and 5x higher in diabetic men and 
women, respectively, compared to control subjects (Kannel and McGee, 1979).  
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The diabetic heart is associated with diastolic and systolic dysfunction, left ventricular 
hypertrophy and enhanced myocardial fibrosis (Marwick, 2008). Several risk factors are 
involved in the pathogenesis of diabetic complications, e.g. glycemic control, hypertension, 
dyslipidemia, diet and smoking (Chiarelli and Marcovecchio, 2013). Here hyperglycemia is a 
vital factor contributing to vascular complications and studies found damaging effects can occur 
in response to both acute and chronic hyperglycemia (Chiarelli and Marcovecchio, 2013). The 
role of hyperglycemia has been shown to be directly associated with vascular complications by 
studies such as the Diabetes Control and Complications Trial (DCCT) and UK Prospective 
Diabetes Study (UKPDS) (Blumenkranz, 1993).   
The diabetic heart is characterized by significant disruptions of metabolic pathways and 
molecular mechanisms needed for physiological cardiac function, e.g. impairment of calcium 
signaling that leads to changes in cardiac contraction and relaxation (Golfman et al., 1996).  In 
addition, increased oxidative stress can activate a plethora of signaling cascades that can result in 
impaired cardiac function, e.g. NF-κB and c-Jun N-terminal kinases by oxidative modifications 
of certain residues (Bayeva et al., 2013). The accumulation of misfolded proteins and 
endoplasmic reticulum stress can also contribute and lead to pathophysiologic outcomes such as 
cardiac apoptosis (Xu et al., 2013). On the metabolic front, diabetic individuals typically display 
reduced myocardial glucose uptake and increased FA utilization (Ungar et al., 2015), with the 
latter fuel known to be detrimental to the myocardium when available in excess (Opie, 1970). 
For example, the diabetic cardiomyopathy is associated with increased reliance on FAs as an 
energy source for the myocardium (Bayeva et al., 2013) that can result in the loss of metabolic 
flexibility (Sharma et al., 2004). Moreover, patients burdened with both type 2 diabetes and HF 
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displayed a significant accumulation of lipids within the myocardium together with a perturbed 
profile of lipid metabolic genes (Sharma et al., 2004).  
4.2 Oxidative stress in diabetes and heart failure 
Oxidative stress can be defined as the imbalance between the generation of ROS/reactive 
nitrogen species (RNS) and intracellular antioxidant capacity (Wang et al., 1998). With diabetes 
the sources of oxidative stress include for e.g. auto-oxidation of glucose, shifts in redox balance 
and attenuated activation of antioxidants such as reduced glutathione (GSH), vitamin E1 and 
antioxidant defense enzymes such as superoxide dismutase (SOD) (Brownlee and Cerami, 1981). 
Moreover, the mitochondrial ETC is an important source of ROS (Chance et al., 1979), while  
NADPH oxidase and uncoupled nitric oxide also make significant contributions to diabetes-
related oxidative stress (Tsutsui et al., 2011). 
4.2.1 The non-oxidative glucose pathways (NOGPs) 
The mechanisms of hyperglycemia-mediated tissue damage are complex but a well-known 
hypothesis posits that ROS plays a central role in this process by activation of downstream, 
damaging metabolic circuits (Brownlee and Cerami, 1981; Nishikawa et al., 2000a, 2000b). Here 
the concept emerges that hyperglycemia leads to mitochondrial superoxide production and 
excess superoxide. This in turn results in DNA damage and the activation of poly (ADP ribose) 
polymerase (PARP) that initiates ribosylation and inhibition of GAPDH. As a result of this 
blockage, upstream glycolytic metabolites are diverted into non-oxidative glucose pathways 
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(NOGPs) with damaging outcomes (Brownlee, 2005).  It is proposed that there is interplay 
between NOGPs and that contribute to detrimental effects to the myocardium such as oxidative 
stress, ROS and cellular dysfunction that are further fueled by hyperglycemia-induced NOGP 
activation (Mapanga and Essop, 2015). These pathways include the polyol pathway, advanced 
glycation end products (AGEs), the hexosamine biosynthetic pathway and the activation of PKC. 
The polyol pathway and AGEs will now be briefly introduced as this was part of the focus of this 
thesis.  
4.2.2 Polyol pathway 
Under physiological conditions in mammalian cells, glucose is phosphorylated by hexokinase to 
G-6-P and enters the glycolytic pathway, while a relatively small proportion enters the polyol 
pathway (Morrison et al., 1970). However, with hyperglycemia flux through the polyol pathway 
accounts for a much higher proportion of glucose metabolism (Cheng and González, 1986). The 
rate-limiting step in the pathway is the reduction of glucose to sorbitol by the enzyme aldose 
reductase (AR) at the expense of nicotinamide adenine dinucleotide phosphate (NADPH) (Yabe-
Nishimura, 1998). Thus higher activation of this pathway will deplete NADPH (Lee and Chung, 
1999). Sorbitol is subsequently converted to fructose by enzyme sorbitol dehydrogenase (SDH) 
with NAD
+
 utilized as a co-factor (Figure 4.1). As NADPH is a critical co-factor in the 
regeneration of the intracellular antioxidant reduced glutathione (GSH), lower availability will 
contribute to an increase in oxidative stress (Brownlee, 2005). Thus hyperglycemia-induction of 
the polyol pathway can increase oxidative stress and thus contribute to downstream effects that 
will impact on cardiac function (Mapanga and Essop, 2015). 
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Figure 4.1. The role of the polyol pathway in triggering hyperglycemia-induced oxidative stress (reproduced 
from Tang et al., 2012). 
4.2.3 AGEs 
AGEs are formed during a Maillard reaction which involves the non-enzymatic reaction between 
sugar residues with a protein amino group to form a Schiff-base (Figure 4.2). This is a rapid 
reaction and can be reversed depending on the concentration of substrate. The Schiff-base is 
subsequently converted into a more stable Amadori product (examples of this reaction include 
glycosylated hemoglobin [HbA1c]). This can be further metabolized to lead to stable and 
irreversible AGE compounds (Miyata et al., 2001a). Hyperglycemia may directly increase AGE 
precursors as a result of the accumulation of G-3-P in the glycolytic pathway which is then 
diverted to form the AGE precursor, methylglyoxal. 
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Figure 4.2. The formation of AGEs (reproduced from Hartog et al., 2007). 
AGEs accumulate with aging and such accrual is also accelerated in diabetic individuals 
associated with detrimental effects (Meerwaldt et al., 2007; Monnier et al., 1999). In addition, 
accelerated dietary intake of AGEs may contribute to pathophysiologic outcomes (Brownlee, 
2001) and thus its effects may not only be limited to diabetic individuals. For example, some 
found an association between non-diabetics and AGEs together with the development and 
progression of HF (Hartog et al., 2007). However, with diabetes the AGEs are also implicated in 
the progression of HF by two key pathways, i.e. 1) affecting physiological components of 
proteins in the extracellular matrix via cross-links and 2) resulting in vascular and cardiac 
changes through its interaction with AGE receptors thereby causing diastolic and systolic 
perturbations (Hartog et al., 2007). Another pivotal precursor of AGEs is known as fructosamine 
(Popova et al., 2010). Of note, the human body is also exposed to exogenous AGEs that are 
present in various foodstuffs (Cai et al., 2012). Therefore, the mechanism of deglycation is an 
important factor in the deceleration of the progression of vascular damage, i.e. there are two 
enzymatic protective systems known as fructosamine 3-kinase (FN3K) and the glyoxalase 
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system involved in decreasing the production of AGEs.  An increased expression of FN3K was 
observed in tissues prone to glycation, e.g. heart, nerves and kidneys (Mohas et al., 2010). 
Fructosamine can be phosphorylated by FN3K which leads to the production of the more 
unstable fructosamine-3-phosphate (Delpierre and Van Schaftingen, 2003). The latter can in turn 
form 3-deoxyglucoasone and phosphate that leads to deglycation of proteins (Delpierre and Van 
Schaftingen, 2003).  3-deoxyglucosone is also a potent precursor for AGE formation (Kusunoki 
et al., 2003). Fructosamines are formed as a result of condensation between glucose and primary 
amines, after which an Amadori product is, produced. The glycation of proteins in diabetes is of 
particular importance for two reasons, i.e. a) the reaction rate is low and directly proportionally 
to glucose concentration (Day et al., 1979; Higgins and Bunn, 1981), and b) levels of glycated 
hemoglobin and serum fructosamines are used to measure blood glucose levels over relatively 
longer time periods. Therefore the latter is commonly utilized to assess the efficacy of treatment 
of diabetic individuals (Armbruster, 1987; Goldstein et al., 1986; Johnson et al., 1983). 
Fructosamines and AGEs are also involved in the development of diabetic complications (Cohen 
et al., 1996).  
Glyoxylase-1 (GLO-1) is an enzyme that catalyzes acyclic alphaoxoaldehydes to derivatives of 
hydroxyacylglutathione.  This results in the inhibition of glycation of methylglyoxal, glyoxal and 
other alphaoxoaldehydes. Oxidative stress and ageing result in an attenuation in GLO-1 levels 
that in turn can lead to an increase in glycation and tissue damage.  A deficiency in GLO-1 is 
also linked to abnormal AGE levels in hemodialysis patients (Miyata et al., 2001b). Moreover, 
GLO-1 knockdown mimics diabetic nephropathy in non-diabetic mice (Giacco et al., 2014). It 
has been recognized that glyoxalase requires glutathione as a cofactor - however glutathione has 
Stellenbosch University  https://scholar.sun.ac.za
 37 
 
no effect on glycolysis (Jowett and Quastel, 1933). The GLO system produces D-lactate that is 
converted to pyruvate by D-lactate dehydrogenase.  Methylglyoxal and the GLO pathway remain 
one of the most mysterious challenges in modern biochemistry. Methylglyoxal is toxic and the 
GLO pathway therefore serves as a protective mechanism that comprises GLO-1 
(lactoylglutathione methylglyoxallyase) and GLO-2 (hydroxyacylglutathione hydrolase) that are 
responsible for the formation of D-lactate from the hemithioacetal formed from methylglyoxal 
and glutathione (Thornalley, 1990).  
The diabetic heart’s signature is thus characterized by damaging effects mediated by FAs (e.g. 
uncoupling of mitochondrial respiration) and also hyperglycemia-mediated effects by pathways 
such as AGEs. Although the diabetic heart takes up lower amounts of glucose, the AGE pathway 
can still be activated by oxidative stress and by poor nutritional intake (e.g. enriched with 
AGEs). These pathways are all relevant within the context of HF and thus provide unique targets 
to test as therapeutic agents – the focus of this thesis. However, we will first provide some 
insights regarding existing treatment options for HF and thereafter shift the focus to metabolic 
modulators such as TMZ. 
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 CHAPTER 5 5
5.1 Current treatments for AHF 
AHF is a major global burden on public health and research.  Current therapeutic strategies are - 
unlike for chronic HF - mainly based on clinical practice instead of evidence generated from 
randomized clinical trials (Murray et al., 2012). Here primary goals involve the stabilization of 
hemodynamics and symptomatic relief (Nieminen, 2005), e.g. stabilizing the patient by 
improving signs and symptoms, correcting volume overload, increasing hemodynamic status and 
counteracting neurohormonal hyperactivation (Nieminen, 2005).  
AHF treatment remains a challenge due to heterogeneity in terms of its presentation and it is 
therefore unlikely that a single treatment modality will be employed for all patients             
(Onay-Besikci and Ozkan, 2008). Current treatment modalities include oxygen, diuretics, 
vasodilators and positive inotropic agents - all with clinical limitations (Nieminen, 2005). For 
example, oxygen is employed to treat hypoxemia (SpO2<90%) but is associated with increased 
risk of short term mortality and it should not be used routinely as it can lead to vasoconstriction 
and decreased cardiac output (Park et al., 2010). Non-invasive ventilations are also frequently 
employed by AHF treatment sites, while invasive ventilation procedures are used in very few 
cases.  
Diuretics (e.g. furosemide) are well established as a cornerstone of therapeutic strategies in this 
instance and result in prompt symptomatic relief. The reliance on diuretics can be understood as 
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the majority of AHF patients present with volume overload and thus this therapeutic strategy 
provides rapid relief of symptoms such as breathlessness. However, some studies demonstrated 
that the use of diuretics can lead to increased mortality (Cooper et al., 1999; Philbin et al., 1997) 
and activation of the neurohormonal response that can in turn trigger cardiac arrhythmias. In 
addition, diuretics may be detrimental to AHF patients who suffer from with acute renal failure 
(Mehta et al., 2002). Vasodilators assist in improving hemodynamics but side-effects include 
tachyphylaxis and    dose-related outcomes (Nieminen, 2005). For example, the Vasodilation in 
the Management of Acute Congestive heart failure (VMAC) study found that tachyphylaxis can 
start within 1 to 2 hours post-therapy (Cuffe et al., 2002).  Positive inotropic agents such as 
dobutamine and milrinone are beneficial to increase cardiac index in patients with low output 
HF, but inotrope usage can also lead to a sub-optimal prognosis (Nieminen, 2005). Such drugs 
act by exerting a positive inotropic action by increasing cyclic adenosine monophosphate 
(cAMP) levels and calcium handling within the myocardium. However, there are insufficient 
studies addressing the safety and efficiency of such drugs employed in AHF management. For 
example, although several studies have focused on the efficacy of dobutamine these have had 
several limitations that include lack of properly controlled studies and relatively small sample 
sizes (Nieminen, 2005). Inotropic drugs are also associated with an increased proarrhythmic risk 
versus other AHF therapeutic agents, e.g. dobutamine can trigger increased ventricular 
tachycardia compared to nesiritide (Burger et al., 2015b). Moreover, there is mounting evidence 
that positive inotropic agent usage in AHF patients is associated with increased mortality (Burger 
et al., 2015a; Silver et al., 2002) and impacting on lengths of hospital stays (Burger et al., 2015b; 
Siostrzonek et al., 2000).   
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Thus to sum up it is clear that conventional treatments for HF are focused on modifying 
hemodynamic effects.  Here many agents function by lowering myocardial oxygen consumption, 
increasing coronary blood supply or by improving ventricular relaxation by redistributing blood 
flow (Marzilli, 2003). However, the efficacy of hemodynamic therapeutic interventions is 
limiting due to the occurrence of a plateau effect in diminishing heart rate and contractility of the 
myocardium. This leads to a failure to control cardiovascular dysfunction and often such patients 
are referred for cardiac re-vascularization (Pepine et al., 1994). According to the ESC 
(McMurray et al., 2013) neurohormonal agents (β-blockers, ACE inhibitors and 
mineralcorticoids) are used to prevent the progression of systolic dysfunction in chronic HF. 
Diuretic agents are often used as combination treatment to relieve symptoms of congestion. Thus 
it is clear that the limitations of current therapies for AHF necessitate the development of novel 
therapeutic agents that will improve both the patient’s prognosis and quality of life.  
Metabolic agents are a new class of drugs that act by optimizing myocardial substrate 
metabolism and hence do not target hemodynamic parameters (Rosano et al., 2015). For 
example, Kantor et al. (Kantor et al., 2000) demonstrated TMZ elicited no significant effects on 
heart rate, systolic pressure, developed pressure and cardiac output.  This study also 
demonstrated that TMZ had no significant effects on oxygen consumption (Kantor et al., 2000).  
Thus the hope remains that such agents should result in improved care of AHF patients and we 
predict this will include less side-effects as typically found with existing treatment modalities.  
As earlier discussed, the failing heart is associated with impaired energy metabolism  (Rosano et 
al., 2015) that includes mitochondrial dysfunction (Van Bilsen et al., 2009) and damaging effects 
of increased FA utilization (Essop and Opie, 2004) (discussed in Chapter 3). Thus the lowering 
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FA utilization and the concomitant increase in glucose metabolism is a feasible paradigm to 
strive for when trying to improve cardiovascular complications in AHF patients (Piatti et al., 
2015).  As the focus of this study is on TMZ as a novel therapy for AHF, the next section will 
further provide background on this unique drug.  
5.2 The ABCs of TMZ 
Trimetazidine (1-[2,3,4-trimethozybenzyl] piperazine (TMZ) is a clinically efficient metabolic 
modulator and a well-tolerated anti-anginal drug (Figure 5.1). It has several cytoprotective 
effects that are beneficial to patients without changing myocardial oxygen consumption or blood 
supply (Chierchia and Fragasso, 1993). TMZ selectively inhibits the long chain isoform of 3-
KAT, the final enzyme of the mitochondrial FA β-oxidation spiral. This results in partial 
inhibition of cardiac FA β-oxidation and the concomitant increase in glucose oxidation (thus 
reversing the Randle effect). Here TMZ treatment helps ‘’couple’’ glycolysis to glucose 
oxidation by increasing PDH activity due to an attenuation of the Randle cycle (Kantor et al., 
2000). Finally, the lowering of such effects will also improve mitochondrial function by 
attenuating FA-mediated uncoupling and ATP depletion.  
  
 
Figure 5.1. The chemical structure of TMZ (Onay-Besikci & Ozkan, 2008). 
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The two main forms of TMZ available on the market are the immediate release (IR) 20 mg tablet 
taken three times a day and the modified release (MR) 35 mg taken twice daily (Servier, 
Suresnes, France). The IR is designed to sustain plasma TMZ levels (Dézsi, 2015), while the 35 
mg dosage allows the drug to maintain anti-anginal efficiency by providing 12 hours of 
cardioprotection (Sellier and Broustet, 2003). It can be administered as monotherapy or 
combination treatment with other anti-anginal agents and is rapidly absorbed by the intestinal 
tract, with the patients fast or fed state having no effect on its bioavailability (Ozbay et al., 
2012).  TMZ has a half-life of approximately 6 hours (Harpey et al., 1988)  and is generally 
well-tolerated with few side-effects (mainly gastrointestinal disturbances, vomiting and nausea) 
(Massó et al., 2005).  
Metabolic agents may be a more effective approach when used as monotherapy or in 
combination with standard therapies as they act by shifting cardiac substrate metabolism without 
inducing any negative hemodynamic effects (Stanley et al., 2005). Since the early 1970s there 
has been increasing evidence of TMZ’s protective effects. This is especially the case within the 
context myocardial ischemia, e.g. it increased cardiac efficiency in pre-clinical (Ikizler et al., 
2006; Kantor et al., 2000; Khan et al., 2010; Lopaschuk et al., 2003) and clinical studies 
(Brottier et al., 1990; Fragasso et al., 2013, 2011, 2006a, 2003; Lu et al., 2015; Marzilli and 
Klein, 2003; Szwed et al., 2001; Vitale et al., 2015, 2004). Clinical trials also demonstrated that 
combination therapy (hemodynamic together with metabolic modulation) to be effective and also 
that it is well tolerated (no significant changes in heart rate, blood pressure and rate pressure 
product) (Detry et al., 1994). Treatment with TMZ for HF and ischemic heart disease patients are 
well documented and its beneficial effects have also been demonstrated in other ischemic organs 
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(Onay-Besikci and Ozkan, 2008). The beneficial effects of TMZ were demonstrated in several in 
vitro and in vivo studies using various models of ischemia and also in clinical trials. There is 
increasing evidence that TMZ improves ischemic injury and cardiac function in animal models 
(Ikizler et al., 2006; Kantor et al., 2000) and in humans (Bui et al., 2011).  For example, elderly 
chronic HF patients that were treated with TMZ displayed improved cardiac output and quality 
of life (Vitale et al., 2004). Additional cytoprotective effects of TMZ may potentially include 
diminished mitochondrial ATP production and a reduction in apoptosis, although further studies 
are required to verify this. Here TMZ could potentially reduce the FA-mediated uncoupling of 
respiration and thereby increase cardiac output (Chandler et al., 2002).  
The efficiency of TMZ to improve HF can be attributed to its modulation of FA metabolism, 
lowering of ROS and subsequent improvement in contractile function (Gambert et al., 2006). A 
randomized clinical trial also demonstrated that TMZ in combination with conventional 
pharmacological agents resulted in improved left ventricular end-systolic volume and ejection 
fraction in HF patients (Fragasso et al., 2006b).  Together the data strongly supports a beneficial 
role for TMZ for CVD treatment, with limited side-effects. However, whether TMZ can offer 
cardioprotection within the context of AHF and with diabetes as a co-existent risk factor remains 
poorly understood.  In light of this, for the current study we hypothesized that TMZ offers 
cardioprotection to diabetic rat hearts subjected to ex vivo AHF.  
The objectives of this study are to 1) establish an experimental diabetic ex vivo rodent model of 
AHF; 2) assess whether the metabolic agent TMZ can improve myocardial contractile function 
with AHF (non-diabetic and diabetic hearts); and 3) determine underlying mechanisms (focusing 
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on polyol pathway and AGEs) driving the onset of AHF in normal and diabetic hearts and 
establish how this altered with TMZ treatment. 
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 CHAPTER 6 6
Materials and Methods 
6.1 Hypothesis 
We hypothesize that metabolic modulation using TMZ protects the myocardium with onset of 
AHF by improving contractile function of the diabetic heart. 
6.2 Aims 
1. Establish an experimental, ex vivo rat model of experimental AHF and evaluate the impact of   
    diabetes within this context. 
2. Assess whether the metabolic agent TMZ is able to improve contractile function with    
    AHF with and without diabetes. 
3. Determine underlying mechanisms driving the onset of AHF in normal and diabetic hearts and    
    assess how this can be altered by TMZ treatment. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 46 
 
6.3 Methodology for model of acute heart failure 
6.3.1 Animals and ethics statement  
All animals were treated in accordance with the Guide for the Care and the Use of Laboratory 
Animals of the National Academy of Sciences (NIH publication No. 85-23, revised 1996). 
Studies were performed with the approval of the Animal Ethics Committee of Stellenbosch 
University (SU_ACUM13-00020) (Appendix A) and (SU_ACUM13-00030) (Appendix B). 
6.3.2 Induction of experimental diabetes Type 1 
Male Wistar rats (180 – 220 g) were injected intraperitoneally (i.p) with a single dose of 
streptozotocin (STZ) (60 mg/kg) as routinely performed in our laboratory (Mapanga et al., 2014) 
to induce experimental diabetes. Control animals were divided into untreated and vehicle groups; 
the latter injected with citrate buffer (0.1 M) (Appendix C). Blood glucose levels were 
determined with the use of an ACCU-CHEK
®
 glucometer (Roche, Basel, Switzerland) a week 
after STZ injection and values > 20 mmol/L indicated the successful induction of diabetes 
(Mapanga et al., 2014). Body weights were recorded prior to Langendorff heart perfusion 
experiments. 
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6.3.3 Conjugation of bovine serum albumin to palmitate for retrograde heart perfusions 
Dialysis tubing (Spectra/Por
®
 dialysis tubing, Fisher Scientific, Waltham MA) was placed into a 
beaker of distilled water to allow the tubing to soften up prior to the addition of conjugated 
solution.  
The fatty acid content of bovine serum albumin fraction V (BSA) (Roche Ltd., Basel, 
Switzerland) (2 x 15 mg) was sent for gas chromotography analysis prior to conjugation. This 
was performed in conjunction with Prof. Wentzel Gelderblom (SA MRC, Tygerberg, South 
Africa).  Here results indicated that the amount of C16 fatty acid was 0.3 mM.  We therefore 
dissolved 3% BSA (Roche Ltd., Basel, Switzerland) in 400 ml of Krebs-Henseleit buffer at 37°C 
while stirring. Separately, palmitic acid (1.2 mM) and sodium carbonate (1.4 mM) were added to 
a solution containing 15 ml distilled water and 10 ml 95% ethanol (Lopaschuk and Barr, 1997). 
To dissolve the palmitate and sodium carbonate this solution was heated to 60°C until all the 
ethanol had evaporated. Once the ethanol was boiled off the palmitate solution was quickly 
added to the warm BSA solution stirred. Upon the addition of palmitate to BSA, the solution 
initially became cloudy thereafter it cleared (resembling a brown beer-type color) indicating the 
successful conjugation of palmitate to BSA. The conjugated BSA:palmitate solution was poured 
into dialysis tubing and the ends of the tubing tied off and placed in a beaker of  Krebs-Henseleit 
buffer (without glucose) and stirred at 4°C overnight.  The final concentration of palmitate was 
1.5 mM. The following day the dialysis tubing was removed from the Krebs-Henseleit buffer and 
the conjugated solution poured into a glass beaker. The solution was adjusted to final volume of 
1 L with Krebs-Henseleit buffer. 
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6.3.4 Langendorff retrograde heart perfusions 
Non-diabetic and diabetic rats were anesthetized using sodium pentobarbitone (100 mg/kg, i.p 
injection) and hearts rapidly excised and immersed in ice cold Krebs-Henseleit buffer which 
contained 11 mM glucose, 118.5 mM NaCl, 25 mM NaHCO3, 4.75 mM KCl, 1.19 mM 
MgSO4.7H2O, 1.18 mM KH2PO4, 1.36 mM CaCl dehydrate for non-diabetics and 30 mM 
glucose, 118.5 mM NaCl, 25 mM NaHCO3, 4.75 mM KCl, 1.19 mM MgSO4.7H2O, 1.18 mM 
KH2PO4, 1.36 mM CaCl dehydrate for diabetic hearts (refer to Appendix D). The aorta was 
rapidly mounted on a cannula connected to our modified Langendorff retrograde perfusion 
model of de novo AHF and perfused with Krebs-Henseleit buffer. A 2.0 silk suture was used to 
tie the heart to the cannula and thereafter a pressure transducer (Stratham MLT 0380/D, AD 
Instruments Inc., Bella Vista, New South Wales, Australia) connected to a balloon (made from 
cling wrap) was inserted into the left ventricle of the heart. The pulmonary artery was cut to 
expel Krebs buffer from the right ventricle. The balloon was inflated with distilled water inside 
the left ventricle and the diastolic pressure was set between 5 – 12 mmHg. The left ventricular 
pressure was maintained between 80 – 120 mmHg for the duration of the stabilization phase. 
Hearts were maintained at 37°C throughout the protocol and monitored with a temperature 
probe. The PowerLab System (AD Instruments Bella Vista, New South Wales, Australia) was 
used and connected to the pressure transducer (Stratham MLT 0380/D, AD Instruments Inc., 
Bella Vista, New South Wales, Australia) and the electrical signaling of the beating heart was 
converted to an electrical signal that was read by the PowerLab System ML410/W (AD 
Instruments Inc., Bella Vista, New South Wales, Australia). The following parameters were 
recorded: heart rate, left ventricular end diastolic pressure (LVEDP), left ventricular end systolic 
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pressure (LVESP), left ventricular developed pressure (LVDP, the difference between LVESP 
and LVEDP, rate pressure product (RPP) (heart rate x LVDP) and maximum velocity of 
contraction (dP/dtmax) that is calculated as the pressure difference in mmHg/sec. The perfusion 
protocol consisted of 3 phases, i.e. stabilization (30 min), AHF (35 min) and the recovery phase 
(30 min). Here non-diabetic and diabetic hearts were perfused with 11 mM and 30 mM glucose, 
respectively, during the stabilization phase at 100 cmH2O and during the recovery phases, ± 1.5 
mM palmitate, at 100 cm H2O perfusion pressure (refer to Figure 6.1). During the AHF phase 
hearts were perfused with Krebs-Henseleit buffer that contained 1.5 mM palmitate and 2.5 mM 
glucose, where the perfusion pressure was reduced to 20 cm H2O. For the control no-AHF, hearts 
(non-diabetic and diabetic) were perfused for 95 min in the stabilization phase. The non-diabetic 
and diabetic end-AHF groups were perfused until the end of the AHF phase. 
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Figure 6.1. Langendorff retrograde perfusion system, modified to an experimental acute heart failure system. The system consists of 3 
phases: Stabilization, AHF and Recovery. 
 
6.3.5 Our AHF model 
An ex vivo diabetic rat heart Langendorff perfusion model of de novo AHF (Figure 6.1) was 
adapted from a previously established non-diabetic rat heart model of AHF (Deshpande et al., 
2010; Opie and Deshpande, 2016; Opie et al., 2010). The de novo AHF model consists of 3 
phases: stabilization, AHF and recovery. Each phase can be independently activated between 
B: 20 cm H2O 
A: 100 cm H2O  C: 100 cm H2O 
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reservoirs by opening the stop cocks. Hearts are under-perfused in order to stimulate systolic 
failure which impairs the hearts ejection (Opie et al., 2010). In each phase buffers were gassed 
with 95% O2/5% CO2 (#801068-RC-A, AFROX, Gauteng, South Africa) prior to and for the 
duration of heart perfusions. 
A: Stabilization  
The stabilization phase took place over a 30 min period at a perfusion pressure of 100 cm H2O, 
constituted with glucose (either 11 mM [non-diabetic] or [30 mM diabetic]) as the sole substrate 
in Krebs-Henseleit buffer. Since ex vivo Langendoff perfusions are typically performed with         
11 mM glucose we used this as baseline glucose concentration in our non-diabetic hearts, where 
diabetic hearts were perfused with high glucose 30 mM to mimic high concentration of 
circulating glucose in diabetic heart. The purpose of this phase is to wash out any metabolites 
and to assess basal functional parameters (heart rate, left ventricular developed pressure (LVDP), 
rate pressure product and maximum velocity of contraction (dP/dtmax). All hearts that had an 
LVDP < 80 mmHg were excluded from the study.  
B: AHF phase 
This phase took place over a 35 min period where the perfusion pressure was reduced to           
20 cm H2O to stimulate AHF associated with systolic dysfunction (Opie et al., 2010) and glucose 
reduced to 2.5 mM with the addition of supraphysiological levels of FAs (1.5 mM palmitate). In 
this phase glucose is reduced to decrease the delivery of glucose and diminish its protective 
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effect at low coronary flow rates and to increase circulating FA uptake. Here the premise is 
employed that increased FAs are associated with detrimental effects in the failing heart (Opie et 
al., 2010). Moreover, Hamilton and Saggerson (1997) indicated that 2.5 mM glucose in 
myocytes is associated with reduced concentrations of malonyl-CoA compared to physiological 
glucose (5 mM) as malonyl-CoA inhibits carnitine palmitoylytransferase-1 (CPT1) activity that 
in turn regulates fatty acid uptake into mitochondria (Lopaschuk et al., 1994) -  will increase FA 
metabolism. It has also been demonstrated that hearts perfused with 1.2 mM palmitate display 
ventricular dysfunction and impaired calcium homeostasis (Aasum and Larsen, 1997). In 
addition a global ischemic model of low-flow perfusion was previously established where the 
perfusion pressure was reduced from 100 cm H2O to 20 cm H2O in order to stimulate ischemia 
(Bricknell and Opie, 1978). Thus our AHF model was based on the same principle where the 
perfusion pressure was reduced to 20 cm H2O to mimic hypotension often associated with AHF 
patients (Deshpande et al., 2010).   
C: Recovery phase 
The duration of this phase was 30 min, where the perfusion pressure is restored to 100 cm H2O 
without altering the palmitate (1.5 mM) concentration, while glucose availability is restored, i.e. 
11 mM and 30 mM (non-diabetic and diabetic hearts respectively). We employed a 1 µM TMZ 
dose as it was previously associated with optimal functional recovery after ischemia-reperfusion 
(Di Napoli et al., 2007). Therefore in our model we perfused hearts ± 1 µM TMZ for the entire 
recovery period. At the end of recovery phase hearts were collected and freeze-clamped in liquid 
nitrogen and stored at -80°C for further analysis.  
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6.3.5.1 Determination of infarct sizes (tetrazolium staining) -hearts exposed to AHF 
protocol 
Male Wistar rats (180 – 220 g) were anesthetized using sodium pentobarbitone (100 mg/kg) and 
by i.p injection. Hearts were subsequently excised, cannulated and perfused on our modified 
Langendorff retrograde perfusion model of de novo AHF. Hearts (non-diabetic and diabetic) 
were perfused for the stabilization and AHF phase. At the end of the AHF phase, hearts were 
removed and 2.0 suture was placed through the heart and stored suspended in a tube at -20°C for 
24 hours in preparation for tetrazolium staining (TTC) (Sigma-Aldrich, St Louis MO). The TTC 
salt staining method involves the use of dehydrogenase enzymes and cofactors in tissues to react 
with TTC salts to form a formazan pigment.  
The following day, hearts were removed from the freezer and allowed to partially thaw. 
Thereafter, hearts were sliced into four even pieces with the use of a scalpel blade. Heart slices 
were placed on paper towel to further defrost. Two buffers, i.e. 100 mM NaH2PO4 (Solution 1) 
and 100 mM Na2HPO4 (Solution 2) were separately prepared. Thereafter, 1% TTC was dissolved 
in 2 parts of Solution 1, and 8 parts of Solution 2 to make up the TTC solution. Heart slices were 
transferred into the TTC solution and placed in a 37°C waterbath for a total of 20 min. After the 
first 10 min, hearts were agitated and thereafter left for a further 10 min at 37°C (a total of 20 
min). Following the 20 min period, heart slices were removed and placed onto paper towel to 
dry. Heart slices were then placed in a dark cupboard in 10% formalin solution for 24 hours. 
Thereafter, hearts were analyzed for infarct size using Image J software (v1.46p; National 
Institutes of Health, Bethesda MD).  
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6.3.6 Mitochondrial protein isolation 
Mitochondria were isolated from frozen tissue with the use of a tissue extraction kit (Abcam, 
Cambridge MA). The appropriate amount of heart tissue was weighed out (0.2 – 0.4 g) and the 
tissue washed twice with the wash buffer provided in the kit. The tissue was homogenized in a 
pre-chilled Dounce homogenizer (Thomas Scientific, United States). Thereafter 1 ml of isolation 
buffer (Appendix E) was added to the homogenizer and 40 strokes were employed to 
homogenize the tissue. The homogenate was successfully transferred to a 2 ml microfuge tube 
and centrifuged at 1,000 g for 10 min at 4°C. The supernatant (crude mitochondria) was 
collected and transferred into a fresh    2 ml microfuge tube and the pellet discarded. Thereafter 
the crude mitochondria was centrifuged a second time at 12,000 g for 15 min at 4°C and placed 
in a new microfuge tube for further analysis. Mitochondrial proteins were used for Western blot 
analysis of SOD2, PDH, 3-KAT and UCP2.     
6.3.7 Western blot analysis 
Hearts were thawed on ice and proteins were isolated by homogenizing heart tissue in modified 
Radio-Immunoprecipitation (RIPA) buffer (Appendix F). Thereafter the homogenates were 
transferred to pre-chilled microfuge tubes and kept on ice. The samples were sonicated for 15 sec 
each, and centrifuged at 4,300 g for 15 min at 4°C. The isolated protein were transferred into a 
microfuge tube and stored at –80°C until needed. Protein samples were quantified using the 
Bradford method (refer Appendix F) and 20 µg protein was used for each sample. Expression 
was evaluated using both total and mitochondrial protein extracts for the following antibodies: 
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BAD, phosphorylated-BAD (Ser 136), PDH (Cell Signaling, Danvers MA), UCP2 (uncoupling 
protein 2), ACCA1 (acetyl-Coenzyme A acyltransferase 1) for long-chain 3-KAT and SOD2 
(superoxide dismutase 2) (Abcam, Cambridge MA) and RAGE (receptor of advanced glycation 
end products) (Abcam, Cambridge MA). Samples were subjected to 10% SDS-PAGE and a 
semi-dry transfer using the Trans-blot
®
 turbo transfer system (Bio-Rad, Hercules CA) (refer full 
protocol in Appendix G). Membranes were blocked with 5% non-fat milk in TBS-T and 
incubated with the appropriate primary antibody at 4°C overnight (Appendix H). This was 
followed by washing of the membrane with TBS-T (20 mM Tris-HCl and 150 mM NaCl, pH7.4 
and 0.1% Tween 20) (3 x 5 min washes) and incubated with the appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibody (1:5000) for an hour at room temperature. 
Membranes were detected with enhanced chemiluminescence (ECL) (Bio-Rad, Hercules CA) 
and visualized using Bio-Rad Chemidoc imaging system (Bio-Rad, Hercules CA). Total protein 
was used as a loading control (Appendix H) and Western blots were analyzed using the Image 
Analysis software (Bio-Rad, Hercules CA). 
6.3.8   Evaluation of oxidative stress 
Frozen heart tissue was used for the evaluation of oxidative stress. We employed four 
measurements of oxidative stress, i.e. conjugated dienes (CDs), thiobarbituric acid reactive 
substances (TBARS), reduced/oxidized glutathione (GSH/GSSG) and the oxygen radical 
absorbance capacity (ORAC) assay. These assays were conducted in conjunction with the 
Oxidative Stress Research Centre at the Cape Peninsula University of Technology (under 
supervision of Dr. Dirk Bester).  
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6.3.8.1 Conjugated dienes (CDs) 
CDs assay is the measurement of early signs of oxidative stress. Hearts (100 mg) were 
homogenized with choloroform:methanol mixture (2:1) followed by vortexing and centrifugation 
(Eppendorf 5810R, Eppendorf, Hamburg, Germany) at 3,000 g for 10 min. The upper layer was 
discarded and the bottom layer transferred into a clean centrifuge tube with the addition of      
100 µl NaCl until completely separated. Thereafter, samples were allowed to dry overnight in the 
fridge. The following day, 700 µl of cyclohexane was added to each sample and vortexed. An 
amount of 200 µl of sample was added to each well in a 96-well plate and read in a Multiskan 
spectrum platereader (Thermo Electron corporation, Waltham, MA) the absorbance taken at    
233 nm against a cyclohexane standard (standard 1 O.D. = 37.5 nmoles) using a platereader (The 
concentration of CDs are expressed as µmol/g protein. The concentration of CDs was determined 
by the use of the following equation: 
Concentration calculation (CDs) 
Beer Lamberts Law 
A = ɛ x C 
C = A/ɛ 
With the extinction co-effienct (ɛ) being 29500 
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6.3.8.2 Evaluation of thiobarbituric acid reactive substances (TBARS) 
Hearts (100 mg) were homogenized in 6.25 µl (4 mM) cold butylated hydroxytolene (BHT) and 
0.2 mM ortho-phosphoric acid. Thereafter, samples were vortexed for 10 seconds followed by 
the addition of TBA reagent     (0.11 M in 0.1 M NaOH). Samples were briefly vortexed and 
heated at 90°C for 45 min. Subsequently, 1000 µl butanol and 50 µl saturated of NaCl was 
added, vortexed and centrifuged (Boeco M240, Boeco, Hamburg, Germany) at 13,700 for 2 min. 
Samples were read immediately (absorbance A532 –A572) and the concentration of TBARS 
expressed as µmol/g. The concentration of TBARS was measure with the following equation:                                    
Beer Lamberts Law 
A = ɛ x C 
C = A/ɛ 
With the extinction coeffcient (ɛ) being 240.98                                                                                                                                
6.3.8.3 Glutathione redox analysis (GSH/GSSG) assay 
The glutathione assay was adapted from Asensi et al. 1999 (Asensi et al., 1999). The ratio of 
reduced (GSH) to oxidized glutathione (GSSG) was also evaluated as a measurement of 
oxidative stress. For the glutathione (GSH) assay, 100 mg heart tissue was homogenized in ice 
cold 15% trichloroacetic acid (2 ml) (TCA) that contained 1 mM EDTA. Thereafter, samples 
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were centrifuged at 15,000 g for 5 min at 4°C and 500 µl of the supernatant used for analyses. 
For the glutathione (GSSG) assay, 100 mg of heart tissue was homogenized in ice cold 6%  
perchloric acid (PCA) (2 ml) containing 3 mM 1-methyl-2-vinyl-pyridinium trifluoromethane 
sulfonate (M2VP) and 1 mM EDTA. The homogenates were centrifuged at 15,000 g for 5 min at 
4°C.  Thereafter, 500 µl of acidic supernatant was used for analyses and samples diluted in 
Buffer A (500 mM NaPO4, 1 mM EDTA).  Samples for the GSH and GSSG assays were 
prepared in triplicates in separate 96-well plates. An amount of 50 µl of the standards, blank or 
samples were added in a microtiter plate, followed by the addition of 50 µl 5,5’ Dithiobis-(2-
nitrobenzoic acid) solution (DTNB). We then added 50 µl of the enzyme solution (glutathione 
reductase), mixed and incubated the plate for 5 min at room temperature. The reaction is started 
by the addition of 50 µl NADPH to each well and the absorbance was measured at 412 nm for 5 
min using a Multiskan spectrum platereader (Thermo Electron corporation, Waltham, MA). The 
linear slope of the standards was used to calculate concentrations according to the following 
formula:  
GSHt = µM x dilution factor (488) (GSH= GSHt – 2GSSG) 
GSSG = µM x dilution factor (60) 
Ratio = (GSHt – 2GSSG)/GSSG = GSH. 
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6.3.8.4 Evaluation of oxygen radical absorbance capacity (ORAC) assay 
Heart tissue (100 mg) was homogenized in 1 ml (7.5 mM) phosphate buffer pH 7.0 using a 
Potter Elvenhjem Telfon pestle and glass tube tissue homogenizer (10 strokes). The homogenate 
was centrifuged at 12, 000 g at 4°C for 10 min. The supernatant of the samples was then de-
proteinized with 0.25 M perchloric acid and centrifuged at 14, 000 g for 15 min. Trolox (500 µM 
stock) was used for the standards (0, 83, 167, 250, 333 and 417 µM). For the Trolox standard 
series we took six centrifuge tubes (marked A – F) and added the appropriate amount of standard 
stock solution and diluents to each tube (refer Appendix J).  To the wells, we added 12 µl of 
standards per well into a 96-well plate. For the sample well an amount of 12 µl was added in 
triplicates. From the fluorescein stock solution (Appendix J), 10 µl was added to 2 ml phosphate 
buffer in a centrifuge tube. Next 240 µl of this solution was added to 15 ml phosphate buffer into 
a 15 ml centrifuge tube. An amount of 138 µl of this solution was added to each well.  Next we 
added 6 ml phosphate buffer to the AAPH solution (preparation in Appendix J), mixed it 
properly and then 50 µl was added to each well. The plate was then placed into fluorescence 
spectrometer - the ORAC method is performed by using the Fluoroskan Ascent platereader 
(Thermo Fisher Scientific Inc., Waltham MA) until zero fluorescence occurs. The results 
obtained were expressed as the ORAC value which refers to the area under the curve of β-PE 
(fluorescein) in the presence of an antioxidant. The ORAC value is calculated by dividing by the 
area under the sample curve by the area under the curve for Trolox (TE). Values were expressed 
as µmol TE/g 
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6.3.9 Evaluation of non-oxidative glucose pathways (NOGPs) 
We employed two commercial kits to evaluate markers of NOGPs. For the polyol pathway we 
used the D-sorbitol colorimetric assay kit (Biovision, Mountain View CA), while AGE 
precursors were evaluated using the OxiSelect™ Methylglyoxal (MG) competitive ELISA kit 
(Cell Biolabs, San Diego CA). To evaluate two pivotal enzymes fructosamine-3-kinase (FN3K) 
and glyoxylase I (GLO-I) involved in deglycation of AGEs we employed two commercial kits 
Human fructosamine-3-kinase (FN3K) ELISA kit (Cusabio Biotech, Baltimore MD) and  the 
Glyoxalase I assay kit (Abnova, Taipei City, Taiwan). 
6.3.9.1 Sorbitol levels (polyol pathway marker) 
A 1 mM working solution of the sorbitol standard was prepared using the stock provided in the 
kit. Fifty µl standards (including reaction blanks) were pipetted in duplicate into 96-well plate to 
generate 0, 2, 4, 6, 8, 10 nmol/well in assay buffer. Proteins were isolated from heart tissue as 
described in section 6.3.7 (Appendix E).  Protein samples were pipetted in duplicates. Thereafter 
50 µl of reaction mix (assay buffer, enzyme mix, developer and probe) was added to both protein 
and standard wells and incubated at 37°C for 30 min. Absorbance was read at 560 nm using a 
microplate reader (EL 600 KC Junior Universal Microplate reader, Bio-Tek Instruments, 
Winooski VT). The concentration of sorbitol (C) was determined from the standard curve (Sa) in 
nmol, sample volume (Sv) and the dilution factor D in the following equation: C=Sa/Sv*D. The 
concentration of D-sorbitol was expressed as µM protein. 
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6.3.9.2 Methylglyoxal levels (AGE marker) 
Immediately before use, 500 ng/mL of methylglyoxal (MG) conjugate was prepared by diluting 
1 mg/mL MG conjugate in 1x conjugate diluent (provided in the kit). A volume of 100 µl of    
500 ng/mL MG conjugate was added to each well to be tested and incubated at 4°C overnight. 
The following day the MG conjugate solution was removed and wells washed twice with          
1x phosphate-buffered saline (PBS) (13 mM NaCl2, 2.7 mM KCl, 8 mM Na2HPO4 and 1.5 mM 
KH2PO4, pH 7.4.). The plate was blotted on paper to remove excess fluid. The wells were 
blocked on an orbital shaker for an hour at room temperature by the addition of 200 µl assay 
buffer. Methylglyoxal-BSA (MG-BSA) standards and blanks were prepared in duplicate by 
dilution series in the concentration range of 0 to 25 µg/mL with assay diluent. Proteins were 
isolated from heart tissue as described in section 6.3.7 (Appendix E). Fifty µl of standard or 
protein samples were added in duplicate to wells of the plate and incubated at room temperature 
on an orbital shaker for 10 min. Thereafter, 50 µl of diluted anti-MG antibody (1:1000) was 
added to each well and incubated on an orbital shaker for an hour at room temperature.  The 
primary antibody was removed and the wells washed 3x with 250 µl 1x wash buffer. A volume 
of 100 µl secondary HRP-conjugated antibody (1:1000) was added to each well and incubated 
for an hour at room temperature. The wells were washed 5x with 250 µl 1x wash buffer. The 
substrate solution was warmed to room temperature and 100 µl added to each well. The plate 
was incubated on an orbital shaker for 20 min at room temperature and the enzyme reaction 
stopped by the addition of 100 µl stop solution to each well. Absorbance was read immediately 
at 450 nm using a microplate reader (EL 800 KC Junior Universal Microplate reader, Bio-Tek 
Instruments, Winooski VT). Optical densities were normalized by subtracting the value of the 
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blank from both the standard and sample wells. The concentration of methylglyoxal was 
expressed as µmol/µg protein. 
6.3.9.2.1 Fructosamine-3-kinase (FN3K) ELISA assay 
The human FN3K ELISA kit (Cusabio Biotech, Baltimore MD) was used to measure levels of 
FN3K. An amount of 100 mg heart tissue was weighed out for all treatment groups, rinsed with 
1x PBS and homogenized in 1 ml PBS. Thereafter, the homogenates were transferred to pre-
chilled microfuge tubes and kept on ice. The samples were sonicated for 15 sec each, and 
centrifuged at 5,000 g for 5 min at 4°C. Proteins were quantified using the Bradford assay. A 20 
ng/ml working solution of the FN3K standard was prepared using the stock provided in the kit, 
thereafter a dilution series was performed. 100 µl standards (including reaction blanks) were 
pipetted in duplicate into a 96-well plate to generate 0, 0.312, 0.625, 1.25, 2.5, 5, 10, and 20 
ng/ml/well. Protein samples were pipetted in duplicates. Thereafter, the plate was covered with 
the adhesion strip provided and incubated for 2 hours at 37°C. Liquid from the plate was 
discarded and 100x biotin antibody was added to each well. The plate was covered with a new 
adhesive strip and incubated for 1 hour at 37°C. Thereafter, each well was aspirated and washed 
three times with 200 µl wash buffer. After the third wash the plate was inverted and blotted onto 
paper towel. A 100 µl HRP-avidin (1x) was added to each well and covered with a new adhesive 
strip and incubated for an hour at 37°C. This was followed by five aspiration and wash steps 
with 1x wash buffer. Ninety µl of 3,3’,5,’-tetramethylbenzidine (TMB) substrate was added to 
each well, incubated and the plate covered (protect from light) for 15 – 20 min at 37°C. We next 
added 50 µl of stop solution to each well. The absorbance was read at 450 nm using a microplate 
reader (EL 600 KC Junior Universal Microplate reader, Bio-Tek Instruments, Winooski VT). 
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The concentration of FN3K (C) was determined from the standard curve (Sa) in ng/ml, sample 
volume (Sv) and the dilution factor D in the following equation: C=Sa/Sv*D. Fn3K was expressed 
as µg/µl protein. 
6.3.9.2.1.1 Glyoxylase-I (GLO-I) 
The glyoxylase I assay kit (Abnova, Taipei City, Taiwan) was used to measure GLO-I. The 
protein concentration was initially determined using the Bradford method. For each sample two 
tubes were required: one for the GLO-I reaction and another for the sample blank; thus each 
sample served as its own blank. An amount of 40 µl of each sample was added to 2 separate 
microfuge tubes. A working solution was prepared for each tube by adding 160 µl Assay Buffer 
with 8 µl Substrate and 8 µl Cosubstrate. For the GLO-1 reaction, we added 160 µl working 
reagent to the GLO-1 reaction tubes and thereafter incubated for 20 min at room temperature. 
After this 70 µl of 4 M perchloric acid was added to each GLO-1 reaction tube, vortexed and put 
on ice for 15 min. Thereafter, samples were centrifuged at 4,300 g and 200 µl of the supernatant 
was transferred to separate wells of the 96-well UV titer plate. For the sample blanks, 70 µl of 
4M perchloric acid was added to each sample blank tube. The tubes were then vortexed and put 
on ice for 15 min. Following the 15 min period, 160 µl working reagent was added to each 
sample blank tube, vortexed and put on ice for 15 min. Thereafter, sample blanks were 
centrifuged for 5 min at 4,300 g and 200 µl of supernatant was transferred to separate wells of 
the 96-well UV titer plate. Optical density was read at 240 nm and the concentration of GLO-1 
was expressed as µg/µl protein.GLO-1 activity was calculated with the use of the following 
equation: 
Stellenbosch University  https://scholar.sun.ac.za
 64 
 
GLO-1 = 175 x (ODsample – ODblank)   x (1.35 x n) 
where ODsample and ODblank are the optical density values of the sample and blank, respectively. 
The dilution factor for de-proteination is 1.35 and n is the dilution factor if a sample dilution is 
required. 
6.4 Methodology for in vitro studies 
Previous studies demonstrated that TMZ can display antioxidant properties after              
ischemia/ reperfusion (Ruiz-Meana, 2005). Therefore we aimed to evaluate the effects of TMZ 
in an in vitro setting. 
6.4.1 Cell culture 
The rat cardiomyoblast cell line, H9c2, was cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) media containing GlutaMAX
TM
 and 25 mM glucose (Invitrogen, Carlsbad CA).  
Media was supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin 
solution (Invitrogen, Carlsbad CA). Cells were cultured as monolayers at 37°C in a humidified 
atmosphere of 95% air and 5% CO2. Culturing was done in T75 flasks and subcultured once 
confluency was reached and cells thereafter trypsinized. The DMEM media in the flask was 
discarded and the cell monolayer was washed with warm (37°C) PBS. PBS was removed and 
cells incubated with 4 ml of 0.25 % trypsin-EDTA (Invitrogen, Carlsbad CA) for 4 mins at 37°C 
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until cells were detached. DMEM was added to the flask to stop trypsinization and followed by 
centrifugation for 3 min at 1,358 g in a Digicen 20-R Ortoalresa centrifuge (Ortoalresa, Spain). 
Cells were counted with the use of a hemocytometer (Lasec, Cape Town, South Africa). Cell 
pellets were resuspended in the appropriate amount of DMEM media and seeded in cell culture 
flasks, or plates or dishes for experimental passaging. DMEM was refreshed every 48 hours or 
24 hours after seeding cells. 
6.4.2 Evaluation of oxidative stress in H9c2 cells by flow cytometry 
We aimed to evaluate oxidative stress in H9c2 cells treated with or without palmitate and 
trimetazidine. H9c2 cardiomyoblasts were cultured as described in section 6.4.1, until 80% 
confluency was reached. Cells were treated for 24 hour period as demonstrated below: 
   - 48                                0                                   21                                  24     Hours 
 
 
Seeding for              500 µM                  500 µM palmitate             flow cytometry 
experiment           palmitate                + 1 µM trimetazidine 
 
 
Figure 6.2. Experimental Timeline: H9c2 cells were seeded and allowed to plate 48 hours prior to palmitate 
treatment for 21 hours. TMZ was added for the final 3 hours of the protocol, followed by flow cytometry analysis 
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As a study by Shi (2009) showed that cardiomyocytes treated with 500 µM palmitate was 
associated with severe mitochondrial damage and apoptosis, we treated the H9c2 cells with this 
dosage. 
6.4.3 Evaluation of intracellular ROS levels by flow cytometry- DCF fluorescence 
H9c2 cells was seeded in T25 flasks and treated as demonstrated in Figure 6.2. Cells were 
washed with warm PBS and trypsinized with 3 ml Trypsin-EDTA (Invitrogen, Carlsbad CA) and 
incubated at 37°C for 4 min to dislodge cells. Five ml warm DMEM media was added to the cell 
suspension and transferred to a 15 ml tube, and centrifuged at 1,358 g for 3 min in a           
Digicen 20-R Ortoalresa centrifuge (Ortoalresa, Spain). The pelleted cells were washed with 
PBS and centrifuged for 3 min.  Freshly prepared DCF working solution was added to the cells 
and incubated for 10 min at 37°C as before. Five hundred µl PBS was added to the pellet before 
flow cytometry analysis was performed (BD FACSAria
™
, Becton Dickinson, San Jose CA). 
Hundred µM H2O2 was used as a positive control and a 488 nm laser and 502LP 530/30 BP 
emission filters were used. A minimum of 10,000 events were analyzed per sample and 
fluorescence intensity was determined by using the geometric mean. Experiments were repeated 
6 – 8 times.  
6.4.4 Evaluation of mitochondrial ROS by flow cytometry  
Cells were cultured and treated as demonstrated in figure 6.2. MitoSOX™ Red mitochondrial 
superoxide indicator (MitoSOX) (Molecular Probes, Eugene OR) was used to detect sources of 
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mitochondrial ROS. MitoSOX™ Red mitochondrial superoxide indicator is a fluorogenic dye 
used for highly sensitive detection of superoxide in live cells. The dye is a live cell permeant 
which rapidly and selectively targets the mitochondria. Upon entry to the mitochondria the dye is 
oxidized by superoxide and exhibits red fluorescence, and has excitation/emission maximum of 
510/580 nm. 
Stock solutions were prepared by dissolving the contents (50 µg) of one vial of MitoSOX
™ 
mitochondrial superoxide indicator in dimethylsulfoxide (DMSO) to a final concentration of         
5 mM. Single use aliquots were stored at – 20°C to protect and wrapped in foil to protect from 
light. Fresh working MitoSOX
™ 
(5 µM) solution was prepared in PBS and working solution 
added to the cells followed by 10 min at 37°C.  
Thereafter cells were centrifuged at 1,358 g for 2 min. Five hundred µl PBS was added to the 
pellet before flow cytometry analysis (BD FACSAria
™
, Becton Dickinson, San Jose CA) and 
100 µM H2O2 was used for positive control sample. 
6.5 Evaluation of fatty acid β-oxidation enzymes 
Since we did not find any changes in PDH and 3-KAT the marker for glucose oxidation and 
TMZ target respectively, we aimed to explore implications of the fatty acid β-oxidation enzymes: 
HADHA/HADHB for medium-chain specific acyl-CoA dehydrogenase and ACAVDL for the 
long-chain specific acyl-CoA dehydrogenase. 
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Experiments were conducted with the use of the fatty acid oxidation human flow cytometry kit 
(Abcam, Cambridge, MA). H9c2 cells were treated as described in section 6.4.2. Cells were 
harvested as a single suspension and fixed with 4% paraformaldehyde for 15 mins and 
centrifuged at 1,358 g for 3 min. The pellet was permeabilized with 1X permeabilization buffer 
(provided in the kit) for 15 mins and centrifuged at 1,358 g for 3 min. Cells were then blocked 
with blocking buffer (provided in the kit) for 15 min and centrifuged at 1,358 g for 3 min. 
Primary antibody (2X) was diluted in blocking/incubation buffer and overlayed onto the pellet 
for 1 hour. Thereafter, the pellet was washed with washing buffer provided in the kit, followed 
by the addition of secondary antibody (diluted in blocking/incubation buffer) for an hour. 
Samples were read with flow cytometry analysis (BD FACSAria
™
, Becton Dickinson, San Jose 
CA).   
6.6 Evaluation of cell death  
Next we aimed to further investigate apoptosis in our in vitro model. The caspase-GLO
®
 assay 
(Promega, Madison, United States) was used according to the manufacturer’s instructions. H9c2 
cells were treated as described in section 6.4.2. To prepare the caspase-GLO
®
 reagent, caspase-
GLO
®
 substrate was added to caspase-GLO
®
 buffer. Equal caspase-GLO
®
 reagent was added to 
each sample, mixed and incubate for 30 min. Thereafter, the plate was read with the use of the 
luminometer (Promega, Madison,United States). Data was expressed as reflective light units 
(RLU). 
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6.7 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM). Differences between treatment 
groups and time-points were analyzed using one way analysis of variance (ANOVA). Mann-
Whitney unpaired t-test was done when comparisons were made between two groups. 
Significance was assessed by means of the Tukey-Kramer post hoc. All statistical analysis was 
performed with the use of GraphPad Prism version 5.01 (GraphPad Software, Inc., La Jolla CA). 
Values were considered significant p<0.05. 
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 CHAPTER 7 7
Results 
Validation of ex vivo perfusion de novo AHF rodent model in non-diabetic and diabetic 
hearts 
7.1 Introduction 
We initially aimed to validate our ex vivo perfusion AHF rodent model in non-diabetic and 
diabetic hearts. Control (i.e. no AHF) hearts were perfused in the stabilization phase for 95 min 
and compared to counterparts subjected to AHF (Section 6.3.5). Our results demonstrate a robust 
decrease in function in the AHF phase for both non-diabetic (p<0.001 vs. non-diabetic control) 
and diabetic hearts (p<0.001 vs. diabetic control) (Figures 7.1 and 7.2).  
This decrease in function is shown by a robust fall (p<0.001) in LVDP,  i.e. for non-diabetic 
control hearts  LVDP ranged between 77.7 mmHg ± 6 mmHg and 92 mmHg ± 4.8 mmHg  vs. 
non-diabetic AHF where it ranged between 8 mmHg ± 2.5 mmHg and 9.8 mmHg ± 6.6  mmHg, 
respectively. During the same period (AHF phase) RPP and dP/dtmax showed a similar pattern 
(Figure 7.1). This was also the case for heart rate.  
During the stabilization phase coronary flow for non-diabetic control hearts ranged between      
11 ml/min ± 0.6 ml/min and 8.5 ml/min ± 0.9 ml/min vs. non-diabetic AHF hearts (10 ml/min ± 
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0.6 ml/min). Of note, coronary flow (non-diabetic hearts) significantly decreased during the AHF 
phase to 3 ml/min ± 0.1 ml/min for both non-diabetic and diabetic hearts and remained like this 
until the end of the AHF period.  
A similar decrease in function was observed in AHF diabetic hearts for all the four parameters 
(Figure 7.2 A – D, p<0.001 vs. diabetic control). RPP for AHF diabetic hearts were also reduced, 
ranging from 195 mmHg/sec ± 52 mmHg/sec to 237 mmHg/sec ± 62  mmHg/sec (Figure 7.2 C, 
p<0.001). We also completed additional experiments where hearts were perfused until the end of 
AHF phase and evaluated for necrosis using TTC staining as described.   Here our data reveal no 
visible evidence of infarction (Figure 7.3). 
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Figure 7.1. Non-diabetic hearts subjected to simulated AHF display a reduction in heart rate, LVDP, RPP and dP/dt 
during the AHF phase versus non-diabetic control hearts. Isolated non-diabetic rat hearts were perfused under baseline 
conditions (11 mM glucose) for 95 min stabilization. The second group was subjected to simulated AHF conditions i.e. 30 min 
stabilization (11 mM glucose), 35 min AHF (2.5 mM glucose, 1.5 mM palmitate) and 30 min of recovery (11 mM glucose, 1.5 
mM palmitate). (A) heart rate, (B) left ventricular developed pressure (LVDP), (C) rate pressure product (RPP), (D) maximal 
velocity of contraction (dP/dtmax). Values are expressed as mean ± SEM (n ≥ 6). ***p<0.001 vs. non-diabetic control. 
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Figure 7.2. Diabetic rat hearts subjected to simulated AHF showed a decrease in contractile function during the AHF 
phase compared to control diabetic hearts. Isolated diabetic control rat hearts were perfused (30 mM glucose) for 95 min 
stabilization. The second group was subjected to simulated AHF conditions i.e. 30 min stabilization (30 mM glucose), 35 
min AHF (2.5 mM glucose, 1.5 mM palmitate) and 30 min of recovery  (30 mM glucose, 1.5 mM palmitate). (A) 
heart rate, (B) left ventricular developed pressure (LVDP), (C) rate pressure product (RPP), (D) maximal velocity of 
contraction (dP/dtmax). Values are expressed as mean ± SEM (n ≥ 6). **p<0.01 vs. diabetic control; ***p<0.001 vs. 
diabetic control.  
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Figure 7.3. Non-diabetic and diabetic rat hearts exposed to the stabilization and AHF phase only. Isolated non-diabetic and 
diabetic rat hearts were subjected to two phases only, i.e. 30 min stabilization (11mM or 30 mM glucose, non-diabetic and 
diabetic respectively), followed by 35 min of AHF  (2.5 mM glucose, 1.5 mM palmitate). At the end of the AHF phase, hearts 
were stained by the TTC method (n=6). 
These data demonstrate that we successfully validated our ex vivo AHF rodent model which 
shows a significant decrease in function in both non-diabetic and diabetic hearts subjected to 
AHF compared to respective controls. Furthermore, our TTC staining results show no visible 
evidence of infarct/necrosis providing additional insights regarding the nature and outcomes of 
the AHF model here employed. We next proceeded to test the effect of TMZ administration in 
response to AHF in non-diabetic and diabetic hearts and whether such treatment can serve as a 
therapeutic agent. 
ND AHF AHF Diabetic 
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7.2 The effect of TMZ treatment on non-diabetic and diabetic hearts subjected to AHF  
Our findings revealed no significant differences in contractile functional parameters for AHF 
non-diabetic hearts treated with TMZ compared to untreated AHF non-diabetic hearts (Figure 
7.5 A – D).  
 
 
 
 
 
 
 
Figure 7.4. TMZ administration does not affect contractile function and heart rate of non-diabetic hearts exposedd to the 
AHF protocol. Isolated rat hearts were perfused under simulated AHF conditions and subjected to 30 min stabilization (11 mM 
glucose), 35 min AHF (2.5 mM glucose, 1.5 mM palmitate) and 30 min of recovery (11 mM glucose, 1.5 mM palmitate ± 1 µM 
TMZ added during the recovery period. (A) heart rate, (B) left ventricular developed pressure (LVDP), (C) rate pressure product 
(RPP) and (D) maximal velocity of contraction (dP/dtmax). Values are expressed as mean ± SEM (n = 6). 
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However, our findings demonstrate that TMZ treatment markedly improved contractile function 
in the AHF diabetic hearts as indicated by the increase in LVDP during the recovery phase 
(Figure 7.5, p<0.01 vs. untreated AHF diabetic hearts). Untreated AHF diabetic hearts exhibit 
poor recovery as indicated by the LVDP data (21.8 mmHg ± 8 mmHg and 38 mmHg ± 13 
mmHg) compared to TMZ-treated AHF diabetic hearts (76 mmHg ± 6 mmHg and 128 mmHg ± 
24 mmHg) during the recovery phase. No significant changes were observed for heart rate, RPP 
and dP/dtmax (Figure 7.6). We also found that AHF diabetic hearts displayed a decrease in 
functional recovery compared to non-diabetic AHF hearts (Figure 7.6A, p<0.05) where it 
improved from 30.7% ± 5 in AHF diabetic hearts to 86.2% ± 11.2 in counterparts treated with 
TMZ (Figure 7.6 and Table 7.1). The dP/dtmax was also significantly decreased in AHF diabetic 
hearts (10 ± 3.9%) vs. ND AHF hearts (50 ± 9%) (Figure 7.6C), followed by an improvement in 
AHF diabetic hearts treated with TMZ (69 ± 8.4%). 
For systolic and diastolic pressures we found no significant changes (Figure 7.7).  Our findings 
also revealed an improved coronary flow in AHF diabetic hearts treated with TMZ (p<0.001) vs. 
untreated AHF diabetic hearts (Figure 7.8). 
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Figure 7.5. TMZ administration blunts cardiac dysfunction in diabetic rat hearts following AHF. Isolated diabetic rat 
hearts were perfused under simulated AHF conditions and subjected to 30 min stabilization (30 mM glucose), 35 min AHF (2.5 
mM glucose, 1.5 mM palmitate) and 30 min recovery (30 mM glucose, 1.5 mM palmitate) ± 1µM TMZ added during the 
recovery phase. (A) heart rate, (B) left ventricular developed pressure (LVDP), (C) rate pressure product (RPP), (D) maximal 
velocity of contraction (dP/dtmax). Values are expressed as mean ± SEM (n≥5). **p<0.01 vs. AHF diabetic. 
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Figure 7.6. Non-diabetic and diabetic rat hearts subjected to simulated AHF showed a significant decrease in contractile 
function compared to non-diabetic AHF hearts demonstrated by the (A) % LVDP, (B) % RPP and % dP/dtmax at the 30 min 
time-point during the recovery phase. Isolated non-diabetic and diabetic rat hearts were subjected to simulated AHF conditions 
i.e. 30 min stabilization (11 mM or 30 mM glucose, non-diabetic and diabetic hearts respectively), 35 min AHF (2.5 mM glucose, 
1.5 mM palmitate) and 30 min of recovery (11 mM or 30 mM glucose, 1.5 mM palmitate). *p<0.05 vs. AHF diabetic; **p<0.01 
vs. AHF diabetic. Values are expressed as mean ± SEM (n = 6) 
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Table 7.1. The effect of TMZ in non-diabetic and diabetic hearts subjected to simulated AHF. Isolated non-diabetic and 
diabetic rat hearts were subjected to simulated AHF conditions, i.e. 30 min stabilization (11 mM or 30 mM glucose, non-diabetic 
and diabetic respectively, 35 min AHF (2.5 mM glucose, 1.5 mM palmitate) and 30 min of recovery (11 mM or 30 mM glucose, 
1.5 mM palmitate). Data are shown for the 30 min recovery timepoint. *p<0.05 vs. ND AHF;**p<0.01 vs. AHF diabetic, 
**p<0.01 vs. AHF + 1µM TMZ. Values are expressed as % mean ± SEM (n=6). 
 
Non-diabetic and diabetic rat hearts during recovery phase (30 min)  
Treatment Group % LVDP 
 
 % RPP % dP/dtmax  
 
 
ND AHF 54.3 ± 6.9 21 ± 7 50 ± 9 
AHF Diabetic 30.7 ± 5 * 18 ± 6  30 ± 8.9 
ND AHF + 1µM TMZ 32.8 ± 8.4 ** 25 ± 10 48 ± 6 
AHF Diabetic  
+1µM TMZ 
86.2 ± 11.22 28 ± 11 61.7 ± 4.8 
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Figure 7.7. TMZ administration leads to no significant changes in systolic or diastolic pressure. Isolated non-diabetic and 
diabetic rat hearts were perfused under simulated AHF conditions and subjected to 30 min stabilization (11 mM or 30 mM 
glucose, non-diabetic or diabetic respectively), 35 min AHF (2.5 mM glucose,  1.5 mM palmitate) and 30 min recovery (11 mM 
or 30 mM glucose, non-diabetic or diabetic respectively, 1.5 mM palmitate) ± 1µM TMZ added during the recovery phase. (A) 
Left ventricular end systolic pressure (LVeSP) and (B) Left ventricular end diastolic pressure (LVeDP). Values are expressed as 
mean ± SEM (n=6). 
 
 
 
Figure 7.8. TMZ administration leads to an improved coronary flow in the diabetic heart. Isolated non-diabetic and diabetic 
rat hearts were perfused under simulated AHF conditions and subjected to 30 min stabilization (11 mM or 30 mM glucose, non-
diabetic or diabetic respectively), 35 min AHF (2.5 mM glucose, 1.5 mM palmitate) and 30 min recovery (11 mM or 30 mM 
glucose, non-diabetic or diabetic respectively, 1.5 mM palmitate) ± 1µM TMZ added during the recovery phase. *p<0.05 vs. 
diabetic;***p<0.001 vs. AHF diabetic. Values are expressed as mean ± SEM (n=6). 
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Thus these data demonstrate that TMZ administration significantly improved the contractile 
function and coronary flow in diabetic hearts subjected to AHF. We therefore next aimed to 
elucidate possible mechanisms whereby TMZ may exert such cardioprotective effects.  
7.3 The effect of TMZ administration on 3-KAT and PDH expression in non-diabetic and 
diabetic AHF hearts  
The best known mechanism of action of TMZ is the inhibition of long-chain 3-KAT activity 
which subsequently leads to the upregulation of PDH activity to stimulate glucose oxidation 
(Kantor et al., 2000). We employed Western blot analysis to evaluate PDH, long-chain 3-KAT 
and UCP2 as markers for glucose oxidation, fatty acid β-oxidation and mitochondrial membrane 
potential respectively. These markers were evaluated in mitochondrial extracts. 
Our findings show no significant changes in PDH and UCP2 expression, however, expression of 
3-KAT was lower in non-diabetic AHF hearts treated (Figure 7.9) with TMZ (p<0.05 vs. non-
diabetic AHF). 
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Figure 7.9. TMZ administration downregulated the expression of long chain 3-KAT. Crude mitochondria were isolated from 
perfused non-diabetic AHF ± TMZ and AHF diabetic ± TMZ for Western blot analysis of pyruvate dehydrogenase and long 
chain 3-KAT.  Values are expressed as mean ± SEM (n=7). *p<0.05 vs. non-diabetic AHF. 
 
 
 
 
 
Figure 7.10. TMZ administration resulted in no changes in mitochondrial PDH expression. Crude mitochondria were 
isolated from perfused hearts and Western blot analysis as described. Values are expressed as mean ± SEM (n=7). 
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Figure 7.11. TMZ administration did not significantly alter mitochondrial UCP2 protein expression. Crude mitochondria 
were isolated from perfused hearts for Western blot analysis. Values are expressed as mean ± SEM (n≤5). 
These data sets indicate that TMZ has no effect on the mitochondrial protein levels of PDH 
(Figure 7.10) and UCP2 (Figure 7.11).  However, the UCP2 data may not be conclusive as the 
number of samples used was low and the error in the data was quite high (Figure 7.11). To gain 
further insights into underlying mechanism in TMZ cardioprotection, we next aimed to look at 
oxidative stress and apoptosis and how this was altered in our experimental system. 
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7.4 The effects of TMZ administration on antioxidant capacity and apoptotic regulation 
As a study by Ruiz-Meana (2005) demonstrated antioxidant properties of TMZ with            
ischemia-reperfusion, we investigated potential antioxidant properties. Here we employed 
Western blot analysis to assess mitochondrial SOD2, CDs, TBARS, GSH/GSSG and ORAC as 
well as pBAD/BAD levels (for total protein fraction) in order to evaluate intracellular 
antioxidant capacity and apoptosis, respectively. Results indicate no significant changes in SOD2 
expression (Figure 7.12). However, we observed an increase in pBAD/BAD (Figure 7.13) ratio 
in non-diabetic AHF (p<0.05 vs.  untreated non-diabetic AHF) and AHF diabetic hearts (p<0.01 
vs. AHF untreated diabetic) treated with TMZ versus respective non-diabetic AHF and AHF 
diabetic controls (Figure 7.13). 
 Our oxidative stress assessments showed no significant changes for CDs, a sensitive marker for 
early changes in oxidative stress (Figure 7.14).  However, TBARS (longer-term marker for 
oxidative stress) were significantly higher at the end of the AHF phase (for both non-diabetic and 
diabetic hearts) suggesting increased oxidative stress at this phase (Figure 7.15). The GSH/GSSG 
was lower for non-diabetic AHF hearts while ORAC was higher for the same group (Figures 
7.16 and 7.17).  Of note, the latter changes were not observed for the diabetic AHF experimental 
group.  
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Figure 7.12. TMZ administration resulted in no significant effect on SOD2 expression. Crude mitochondria were isolated 
from perfused hearts and Western blot analysis as described. Values are expressed as mean ± SEM (n=7). 
 
 
Figure 7.13. The 
expression of pBAD/BAD is significantly increased in non-diabetic and diabetic AHF hearts treated with TMZ. Total 
proteins were isolated from perfused hearts and Western blot analysis was used to evaluate the expression of pBAD/BAD. Values 
are expressed as mean ± SEM (n≤6). *p<0.05 vs. ND AHF; **p<0.01 vs. AHF diabetic. 
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Figure 7.14. TMZ administration resulted in no significant effect on levels of conjugated dienes. Total proteins were 
isolated from perfused hearts and used to measure conjugated dienes. Isolated non-diabetic and diabetic rat hearts were subjected 
to simulated AHF conditions, i.e. 30 min stabilization (11 mM or 30 mM glucose, non-diabetic and diabetic respectively, 35 min 
AHF (2.5 mM glucose, 1.5 mM palmitate) and 30 min of recovery (11 mM or 30 mM glucose, 1.5 mM palmitate). An additional 
group was added where non-diabetic and diabetic hearts were only perfused until the end of the AHF phase (non-diabetic end-
AHF and diabetic end-AHF). Values are expressed as mean ± SEM (n=6). Values were expressed as µmol/g protein.  
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Figure 7.15. TBARS are increased during the AHF phase in non-diabetic and diabetic hearts. Total proteins were isolated 
from perfused hearts and used to measure TBARS. Isolated non-diabetic and diabetic rat hearts were subjected to simulated AHF 
conditions, i.e. 30 min stabilization (11 mM or 30 mM glucose, non-diabetic and diabetic respectively, 35 min AHF (2.5 mM 
glucose, 1.5 mM palmitate) and 30 min of recovery (11 mM or 30 mM glucose, 1.5 mM palmitate). An additional group was 
added where non-diabetic and diabetic hearts were perfused only until the end of the AHF phase (non-diabetic end-AHF and 
diabetic end-AHF). Values are expressed as mean ± SEM (n=6).Values were expressed as µmol/g protein. *p<0.05 vs. ND AHF 
+ 1µM TMZ;**p<0.01 vs. Diabetic end-AHF; ***p<0.001 vs. AHF Diabetic + 1 µM TMZ. 
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Figure 7.16. TMZ treatment and changes in GSH/GSSG. Total proteins were isolated from perfused hearts and used to 
measure conjugated dienes. Isolated non-diabetic and diabetic rat hearts were subjected to simulated AHF conditions, i.e. 30 min 
stabilization (11 mM or 30 mM glucose, non-diabetic and diabetic respectively, 35 min AHF (2.5 mM glucose, 1.5 mM 
palmitate) and 30 min of recovery (11 mM or 30 mM glucose, 1.5 mM palmitate). An additional group was added in which non-
diabetic and diabetic hearts were only perfused until AHF (non-diabetic end-AHF and diabetic end-AHF). Values are expressed 
as mean ± SEM (n=6). 
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Figure 7.17. Hearts subjected to simulated AHF conditions and ORAC changes. Isolated non-diabetic and diabetic rat hearts 
were subjected to simulated AHF conditions i.e 30 min stabilization (11 mM or 30 mM glucose, non-diabetic and diabetic 
respectively, 35 min AHF (2.5 mM glucose, 1.5 mM palmitate) and 30 min of recovery (11 mM or 30 mM glucose, 1.5 mM 
palmitate). An additional group was added in which non-diabetic and diabetic hearts were only perfused until AHF (Non-diabetic 
end-AHF and diabetic end-AHF). Values are expressed as mean ± SEM (n=6).  
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7.5 Evaluation of NOGP activation in hearts subjected to AHF 
We next determined the effects of NOGP activation on hearts subjected to AHF and how this 
may be altered with TMZ administration. Here we initially evaluated methylglyoxal as a marker 
of the AGE pathway. AHF diabetic hearts treated with TMZ, showed a significant decrease in 
methylglyoxal (p<0.05 vs. AHF diabetic) (Figure 7.18). However, we observed no changes in 
AGE protective systems GLO-I (Figure 7.19), RAGE (Figure 7.20) and FN3K (Figure 7.21) 
expression.  
 
 
 
Figure 7.18. Methylglyoxal levels were downregulated in AHF diabetic hearts treated with TMZ. Values are expressed as 
mean ± SEM (n≤6). *p<0.05 vs. AHF diabetic. 
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Figure 7.19. Trimetazidine administration has no effect on glyoxylase I. Values are expressed as mean ± SEM (n=6). 
 
 
 
Figure 7.20. Trimetazidine administration has no significant effects on the expression of the receptor for advanced 
glycation end products. Total protein was extracted and subjected to Western blot analysis. Values are expressed as mean ± 
SEM (n=6). 
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Figure 7.21. Fructosamine-3-kinase levels remain unchanged in non-diabetic and diabetic AHF hearts ± TMZ. Values are 
expressed as mean ± SEM (n≤6).  
We also assessed activation of the polyol pathway that was upregulated in AHF diabetic hearts 
subjected to TMZ treatment (Figure 7.22).  
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Figure 7.22. Polyol pathway assessment (D-sorbitol levels) with AHF ± TMZ treatment. Values are expressed as mean ± 
SEM (n≤6). *p<0.05 vs. AHF diabetic. 
7.6 Evaluation of oxidative stress in an in vitro setting using H9c2 rat cardiomyoblasts 
Since the in SOD2 expression data did not reveal useful information regarding the potential 
antioxidant effects of TMZ, we further evaluated this within an in vitro setting.  Here we used 
H9c2 cells treated ± palmitate ± TMZ and assessed the levels of intracellular ROS (DCF 
staining) and mitochondrial (MitoSOX staining) ROS levels by flow cytometry. Our results 
indicate that treatment of H9c2 cells with palmitate leads to increased mitochondrial ROS 
(p<0.01 vs. control) and that TMZ attenuates this (Figure 7.23 B). Of note, our treatments 
elicited no significant effect on total intracellular ROS as determined by DCF staining (Figure 
7.23 A). 
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Figure 7.23. Mitochondrial ROS is lowered in response to TMZ treatment. H9c2 cells were subjected to 500 µM palmitate 
treatment for 21 hours and treated with TMZ for the next 3 hours. (A) Total intracellular ROS (DCF), (B) Mitochondrial ROS 
(MitoSOX). Values are expressed as mean ± SEM (n≥5). **p<0.01 vs. control; ***p<0.001 vs. control. 
7.7 Increased caspase 3/7 activity in response to palmitate treatment in H9c2 cells 
To further elucidate the protective effects of TMZ treatment we next evaluated caspase 3/7 
activity, hydroxyacyl-CoA dehydrogenase (HADHA/HADHB) and acyl-CoA dehydrogenase 
very long chain (ACADVL) as markers of apoptosis and FA oxidation, respectively. Our results 
indicate that H9c2 cells treated with palmitate displayed an increase in caspase 3/7 activity 
(p<0.001 vs. control) (Figure 7.24 A). However, there were no significant differences with TMZ 
treatment as well as for HADHA/HADHB and ACADVL expression levels (Figure 7.24 B and 
C). 
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Figure 7.24. Palmitate treatment increased caspase 3/7 activity.  H9c2 cells were subjected to 500 µM palmitate treatment for 
21 hours and treated with TMZ for an additional 3 hours. (A) HADHA/HADHB levels, (B) ACADVL levels, (C) Caspase 3/7 
activity. 
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 CHAPTER 8 8
Discussion 
AHF is a complex life-threatening complex condition that requires rapid therapeutic 
interventions in order to alleviate associated, damaging outcomes (McMurray et al., 2013).  
However, current AHF treatments primarily focus on providing hemodynamic stabilization and 
symptomatic relief (Nieminen, 2005). As such therapies can elicit detrimental side-effects (refer 
Chapter 4 of this thesis) there is an urgent need for the development of novel therapeutic 
interventions.  For this study we therefore focused on metabolic modulation and investigated the 
anti-anginal drug TMZ as a therapeutic intervention for AHF. TMZ classically functions by 
inhibiting FA β-oxidation and favoring glucose oxidation (Kantor et al., 2000) that should limit 
the damaging effects of FAs that occur with HF (Essop and Opie, 2004).  We thus hypothesized 
that acute TMZ treatment offers cardioprotection to diabetic rat hearts subjected to ex vivo 
AHF. The main outcomes of this study were: 1) the successful establishment of an ex vivo 
diabetic rat model of AHF; 2) TMZ blunts cardiac dysfunction in diabetic hearts subjected to 
AHF; and 3) TMZ treatment downregulates myocardial AGEs in diabetic hearts exposed to 
AHF. 4) Our cell data indicate that TMZ may mediate some of its cardioprotective effects by 
attenuating ROS.      
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8.1  The successful establishment of an ex vivo diabetic rat model of AHF  
We initially set out to establish an ex vivo perfusion diabetic rat model of de novo AHF that 
consists of three components, i.e. 1) stabilization phase - characterized by a perfusion pressure of 
100 cm H2O where the sole fuel substrate was either 11 mM glucose (non-diabetic hearts) or 30 
mM glucose (diabetic hearts); 2) AHF phase - characterized by lowering the perfusion pressure 
to 20 cm H2O and the glucose concentration in the perfusate to 2.5 mM. In parallel, FFA 
availability was raised to supraphysiological concentrations (1.5 mM) to mimic elevated levels 
usually found in the failing heart; and 3) recovery phase - perfusion is returned to 100 cm H2O 
without altering the palmitate (1.5 mM) concentration, while glucose availability is restored to 
11 mM and 30 mM for non-diabetic and diabetic hearts, respectively (Figure 6).  
To our knowledge this is one of a few, if not the first, to establish an ex vivo model of AHF for 
the diabetic rat heart. This developmental component of this study was very challenging and 
technically demanding. This consumed a substantial amount of time allocated for completion of 
the study.  However, after repeated attempts and optimization steps we were able to successfully 
establish the model in our laboratory and this advance should now facilitate testing of additional 
therapeutic agents in the setting of ex vivo AHF.  We also provide additional insights into the ex 
vivo AHF model as we now include assessments of changes at the end of the AHF phase.  Here 
the collective data show a sharp decline in heart function together with lower coronary flow 
following AHF. Of note, changes in our coronary flow (Figure 7.8) data were expected as 
pressures are reduced in our model of AHF - to 20 cm H2O. The reduction in coronary flow 
during the AHF phase isn’t as a result of heart failure but rather the reduction in the perfusion 
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pressure. In addition, there is increased apoptosis (pBAD/BAD) (Figure 7.13). However, there 
was no evidence of increased infarct sizes (Figure 7.3) in both non-diabetic and diabetic perfused 
hearts. Of note, an ex vivo ischemia-reperfusion model is also accompanied by a low-flow phase 
as in our AHF model. What are the differences between our AHF model and a ischemia-
reperfusion model? The ex vivo ischemia-reperfusion model has either global or regional 
ischemia with reduced oxygen and nutrient supply to the heart. In comparison to our AHF 
model; our low-flow phase has constant oxygenated nutrient supply to the heart. Secondly 
ischemia is often accompanied by necrosis which is absent in our model. This was a somewhat 
unexpected finding as we postulated increased necrosis following AHF. We are unclear why this 
may be the case and suggest that additional experiments be completed with larger sample sizes in 
order to confirm whether this is indeed the case.  In addition, an assessment of both molecular 
and histological markers of necrosis may also provide further insights into this issue. We also 
found that there is evidence of increased oxidative stress after AHF (higher TBARS) – in both 
diabetic and no-diabetic hearts (Figure 7.15). In support, there is increased ORAC  (Figure 7.17) 
in non-diabetic hearts indicating an attempt to counteract this stress.  However, this was not 
found in the diabetic heart and suggests that this could potentially compromise its ability to 
recover optimally during the recovery phase.  This may therefore be a potential reason why 
diabetic hearts show greater impairment during the recovery phase when compared to non-
diabetic counterparts. However, the GSH/GSSG (Figure 7.16) data do not support this notion as 
non-diabetic hearts exhibited lower levels after AHF.  We are unclear why this may be the case 
and further studies are required to validate this finding.  
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How does the current model differ from the well-established ischemia-reperfusion experimental 
system?  The AHF model has a constant flow of CO2/O2 gassed nutrient Krebs buffer throughout 
all three phases of the protocol that distinguishes it from the classical ischemic heart protocol. 
For the latter, ischemia is simulated by decreasing or completely cutting off the flow of 
oxygenated nutrients to the heart (Sakai et al., 2016). In our opinion, this is one of the key factors 
that distinguishes the ex vivo AHF model from a classic ischemia-reperfusion model. 
Our functional data revealed a robust decrease in contractile function during the AHF phase for 
both non-diabetic and diabetic hearts (Figure 7.1 and 7.2). These data (for non-diabetic hearts) 
are in agreement with the ex vivo rat model established by others (Opie et al., 2010). The 
findings also demonstrate that the combination of diabetes together with AHF results in a more 
damaging outcome compared to the non-diabetic AHF hearts and may occur due to a lack of 
anti-oxidant capacity. The established model is therefore ideal to further test therapeutic 
interventions for conditions where diabetes co-presents with AHF.   
8.2 TMZ blunts cardiac dysfunction in diabetic hearts subjected to AHF 
When TMZ was acutely administered we found that it blunted cardiac dysfunction only in the 
diabetic heart. Here such treatment improved contractile functional parameters during the 
recovery period (Figure 7.5). With regard to LVeSP and LVeDP we observed a trend where the 
systolic pressure was slightly elevated and the diastolic pressure decreased in AHF diabetic TMZ 
hearts, although not statistically significant (Figure 7.7). The latter indicates a potential 
improvement in the filling of the heart. As the model generated is novel, there are no published 
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animal studies that will allow for a comparative analysis of findings generated in this study. 
However, there are clinical studies that agree with our data.  For example, some demonstrated 
improved contractility in the diabetic heart by TMZ treatment (Rosano et al., 2006), while others 
showed that it decreased FA oxidation and increased glucose oxidation in diabetic patients with 
chronic HF, together with improved cardiac function (Monti et al., 2006).  
TMZ classically functions by selectively inhibiting long-chain 3-KAT, the final enzyme in the 
FA β-oxidation spiral (Kantor et al., 2000) and this in turn increases glucose oxidation by 
upregulating PDH. In light of this, we assessed the cardiac expression levels of long-chain         
3-KAT and PDH. The 3-KAT protein levels were lower with AHF as expected, although this 
was not the case for AHF together with diabetes (Figure 7.9). Moreover, PDH protein levels 
were not significantly altered by TMZ treatment (Figure 7.10). Of note, MacInnes et al. (2003) 
found that TMZ did not inhibit long-chain 3-KAT enzyme activity as expected (MacInnes et al., 
2003) and the authors suggested that TMZ may exert its beneficial effects by other mechanisms. 
We are uncertain why TMZ treatment resulted in differences in 3-KAT expression data (AHF 
versus AHF + diabetes) and found no additional literature to further help elucidate such 
discordant findings.  In light of this, we propose that future studies should a) determine 3-KAT 
and PDH enzyme activities and b) evaluate additional TMZ targets.   
8.3 TMZ may mediate some of its therapeutic effects by attenuating the AGE pathway      
As the failing heart is also associated with diminished mitochondrial respiration, greater ROS 
production and increased apoptosis we evaluated protein expression levels of several markers of 
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such processes. Here the data revealed a significant increase in pBAD/BAD expression in both 
non-diabetic and diabetic hearts treated with TMZ. These findings therefore show that TMZ 
triggers anti-apoptotic effects in acutely failing hearts.  Of note, the effect was observed in both 
non-diabetic and diabetic hearts, although TMZ did not result in improvement of cardiac 
function in the former group.  Thus it is likely that TMZ is also acting on other damaging 
pathways that are specifically activated within the diabetic heart. TMZ did not exert any 
significant anti-apoptotic effects our in vitro model (H9c2 cardiomyoblasts) - in response to high 
FA availability. Although there was a modest decrease in caspase activity with TMZ treatment, 
this effect was not statistically significant. The differences between apoptosis data generated by 
the ex vivo and in vitro models may be due to the nature of experimental systems (in vitro versus 
ex vivo), different TMZ dosages employed and also the length of treatments.  Further studies are 
required to reveal the precise reasons for such differences.  
As a study by Ruiz-Meana (2005) demonstrated antioxidant properties of TMZ with ischemia-
reperfusion (Ruiz-Meana, 2005), we investigated its potential antioxidant capacity by completing 
various assessments. To gain additional insights, we evaluated the direct effects of TMZ on 
oxidative stress in H9c2 cardiomyoblasts. Here TMZ treatment resulted in a significant decrease 
in mitochondrial ROS generation (Figure 7.24) and this finding is consistent with the premise 
that it acts on additional intracellular targets to elicit its therapeutic effects. However, our data 
generated from heart tissues collected at the end of the recovery phase are not consistent with the 
in vitro findings.  Here we found that TMZ treatment did not result in significant changes for any 
of the oxidative stress markers evaluated in this study.  Thus the question whether TMZ indeed 
acts as an anti-oxidant mediator in our experimental system remains unclear and further studies 
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are required to resolve the matter.  We propose that a time-dependent study be conducted where 
heart tissues are collected at various time intervals following the AHF phase. It is possible that 
TMZ effects may occur relatively earlier-on during the recovery phase and may thus be missed 
by the time measurements are done at the end of the recovery phase. It is interesting to speculate, 
however, that TMZ is likely to act as an anti-oxidant but that this occurs shortly after the AHF 
phase in especially diabetic hearts, as the latter did not show the increased ORAC response after 
AHF (as for non-diabetic hearts). This makes for an interesting hypothesis to be further 
investigated.   
It is also likely that by blunting FA oxidation in diabetic-AHF hearts TMZ should lower ROS 
production and downstream effects such as cardiac apoptosis (Essop and Opie, 2004).  In 
parallel, TMZ may also act directly on the machinery that regulates cardiac oxidative stress. As 
oxidative stress depends on the balance between the generation of free radicals (largely by 
mitochondria) and its removal by anti-oxidant systems, additional in vitro studies are required to 
more directly test this proposal. Our data suggest that TMZ likely acts by limiting mitochondrial 
ROS generation (Figure 8.1) and not via the antioxidant surveillance systems as SOD2 
expression levels, CDs, TBARS and ORAC did not change especially during the recovery phase.  
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Figure 8.1. Treatment with TMZ improves recovery in diabetic hearts subjected to AHF 
Since our laboratory previously implicated NOGPs as key mediators of diabetes-induced damage  
to the heart (Mapanga and Essop, 2015), we investigated the effects of TMZ on the AGE and 
polyol pathways.  Here TMZ treatment resulted in a significant decrease in myocardial AGEs 
together with increased polyol pathway activation in diabetic-AHF hearts. The finding of higher 
polyol pathway activation (Figure 7.22) with TMZ treatment was surprising as this usually 
associated with damaging effects on the diabetic heart (Mapanga and Essop, 2015). We are 
uncertain regarding the mechanism of such activation and one possibility may be that as glucose 
metabolism increases there may be some ‘’spill over’’ into the polyol pathway.  However, 
additional studies are required to assess the link between TMZ and activation of the polyol 
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pathway in the diabetic heart. Our laboratory recently proposed that AGEs are the most 
damaging of the NOGPs in the diabetic heart (Mapanga and Essop, 2015) and hence it is likely 
that additional cardio-protective effects of TMZ may be mediated by blunting of this pathway. In 
agreement, AGEs are implicated in the progression of HF and may result in both vascular and 
cardiac changes (Hartog et al., 2007).  In support, Brownlee and colleagues established that the 
diabetic heart is associated with increased myocardial AGEs (Brownlee and Cerami, 1981). How 
does TMZ decrease the AGE pathway?  This is unknown at present as this is the first study to 
uncover this link. We attempted to address this question by completing an evaluation of various 
markers of the AGE pathway but found no significance.  Together our data suggest that TMZ 
likely does not exert its protective effects via the AGE pathway and hence it may acting via 
alternative pathways not here investigated. It is possible that the antioxidant effects of TMZ may 
lead to decreased AGE activation, as previously highlighted the link of ROS-mediated AGE 
activation with diabetes (Mapanga and Essop, 2015).  
As previously mentioned our AHF model was adapted from an existing AHF model established 
by Deshpande et al., 2010. These authors focused on deciphering molecular markers and in 
addition they used pacing and altered concentrations of adrenaline, calcium, glucose and 
increased FA during AHF phase. In our study we focused on increased FA and reduced glucose 
in our perfusate to mimic metabolic alterations that occur in the failing heart. In addition the core 
of our model was that it was a diabetic AHF model of AHF. Seeing as though diabetes is 
accompanied with increased mortality in CVD inclusive of metabolic derangements such as 
reduced glucose uptake and elevated blood glucose and FAs (Aronson et al., 1997; Malmberg, 
1997; Nesto and Zarich, 1998).The advantage of our model is to our knowledge it’s the first to 
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test diabetic hearts in the context on AHF and this adds great value to our current knowledge. 
This opens an exciting opportunity for further studies in the field. However, the disadvantage is 
that we investigated AHF in the context of an ex vivo model although this is widely used in 
science it would be beneficial to attempt these studies in an in vivo setting. Secondly, our system 
is a representation of hypotensive AHF and it would be beneficial to test this model in the 
context of hypertensive AHF model.  
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8.4  Limitations of the study 
For the Western blot analysis we did not include non-AHF control samples due to technical 
reasons (lack of adequate sample materials) - generation of such data would have added value to 
our understanding of the ex vivo AHF model here established. As hypertensive HF is the most 
common form of AHF in sub-Saharan Africa, future studies should be geared toward 
establishing a diabetic hypertensive AHF model which would add even greater insights into 
treatment strategies for AHF.  For example, others found that ex vivo perfusions with pressures  
180 mmHg lead to irreversible heart failure (Opie, 1965); this would therefore be a useful 
starting point to establish such an experimental model. 
8.5 Conclusion  
To our knowledge our study is the first of its kind to demonstrate that TMZ can improve 
contractile function in diabetic hearts subjected to de novo AHF. This opens up an exciting 
option for the treatment of AHF as TMZ acts by metabolic modulation and therefore elicits no 
hemodynamic effects. TMZ offered cardioprotection in diabetic hearts exposed to AHF. Our 
results indicate that TMZ reduces detrimental myocardial AGEs in diabetic hearts. However, we 
propose that TMZ may potentially trigger its protective effects by lowering mitochondrial ROS 
as indicated in our cell work. This requires further confirmatory studies and TMZ therefore 
emerges as a putative therapeutic target to be considered as sole and/or combined treatment (with 
more conventional drugs) for AHF patients.  However, further studies are required to confirm 
this notion and to translate such basic research work into the clinical setting.     
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Appendix C 
Preparation of citrate buffer for dissolving streptozotocin 
An amount of 0.192 g citric acid (0.1 M) was dissolved in 10 ml dist H20 (Solution A) and 
separately 0.294 g sodium citrate (0.1 M) was dissolved in 10 ml (Solution B). An amount of   
1.8 ml of Solution A was added to 8.2 ml Solution B and brought to a final volume of 100 ml 
with dH20. The pH was adjusted to 6.2 with sodium hydroxide or hydrochloric acid. 
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Appendix D 
Preparation of Krebs-Henseleit buffer  
Krebs-Henseleit stock solutions 
1. NaCl (277 g/2 L) (118.5 mM) 
2. NaHCO3 (84 g/2 L) (25 mM) 
3. KCL (11.8 g/1 L) (4.75 mM) 
4. MgSO4.7H20 (9.8 g/L) (1.19 mM) 
5. KH2PO4 (8g/L) (1.18 mM) 
6. CaCl2 dehydrate (20 g/L) (1.36 mM) 
To prepare a 5 L Krebs-Henseleit buffer, mix 250 ml of solution 1 and 2, add 150 ml of solution 
3 and 4. Thereafter add 5 and 6 and stir the solution. Add the appropriate amount of glucose, 
either 10 g (11 mM) for baseline glucose or 27 g (30 mM) for high glucose concentrations. 
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Appendix E 
Mitochondrial protein isolation 
The Isolation buffer provided in the mitochondrial isolation kit (Abcam, MitoSciences,Eugene 
OR) was supplemented with the following protease inhibitors:   
- 1 mM phenylmethylsulfonyl (PMSF) added before use 
- 1 µg/ml leupeptin 
- 1 µg/ml aprotonin 
- 1 mM sodium orthovanadate (Na3VO4) 
- 1 mM sodium fluoride (NaF) 
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Appendix F 
Modified RIPA buffer 
For 100 ml of modified RIPA buffer 
- 50 mM (790 mg) Tris base to 75 ml dH20. Add 900 mg NaCl. Adjust the pH to 7.4 using 
HCL. 
- 10 ml 10% Nonidet-P40 (NP-40) (final concentration of 1%) 
- 2.5 ml of 10% sodium-deoxycholate (final concentration 0.25%) 
- 1 mM EDTA, pH 7.4 (final volume of 100 ml) 
- 1 mM phenylmethylsulfonyl (PMSF) added before use 
- 1 µg/ml leupeptin (10 µl) 
- 1 µg/ml aprotonin (10 µl) 
- 1 mM sodium orthovanadate (Na3VO4) (final volume of 100 ml) 
- 1 mM sodium fluoride (NaF) (final volume of 100 ml) 
- 1% Triton X 
This buffer is made to 100 ml with dH2O, aliquoted and stored at – 20°C 
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Appendix G 
Bradford protein quantification 
 
Bradford stock solution (5x) 
Dilute 500 mg Coomassie Brilliant blue G250 in 250 ml 95% ethanol 
Add 500 ml phosphoric acid, mix thoroughly 
Adjust volume to 1 L with dH20 
Filter solution and store at 4°C 
 Bradford working solution  
 Dilute stock solution in a 1:5 ratio with dH20 
 Filter with 2 filter papers 
  * The filtered working solution should be light brown in color: light sensitive 
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Bradford method 
1. Thaw  1 mg/ml BSA stock (stored in freezer) 
2. Thaw protein samples on ice - keep in ice at all times 
3. Prepare BSA working solution by diluting 100 µl BSA stock in 400 µl dH2O, vortex 
4. Label 7 tubes for the standard curve and 1 tube for each sample. Samples were prepared 
in duplicate 
5. Add BSA and dH2O according to the table below 
 
          Standard (µg protein)                         BSA (µl)   dH2O (µl) 
 
                 Blank                                               0                                         100 
                   2                                                   10                                          90 
                   4                                                   20                                          80 
                   8                                                   40                                          60 
                  12                                                   60                                          40 
                  16                                                   80                                          20 
                 20                                                  100                                           0 
 
6. Add 95 µl dH2O and 5 µl protein sample (tissue or cell proteins) 
7. Vortex all tubes briefly 
8. Add 900 µl Bradford working solution to each tube and vortex again 
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9. Incubate tubes at room temperature for 5 min 
10. Switch on the spectrophotometer, allow it to calibrate, then set the wavelength to 595 nm 
11. Read absorbance of standards and samples twice for each tube 
12. If the absorbance of samples fall outside the range of the highest standard, dilute with 
RIPA 
13. Use Bradford graph program to plot a standard curve and unknown protein (µg) values. 
14. Prepare samples with loading buffer of equal protein amounts (µg) 
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Appendix H 
Western blot protocol 
Preparation of sample buffer 
Laemmli sample buffer 
dH2O – 3.8 ml 
0.5 M Tris-HCL, pH 6.8 - 1 ml 
Glycerol – 0.8 ml 
10% (w/v) SDS -1.6 ml 
0.05% (w/v) bromophenol blue – 0.4 ml 
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Sample preparation 
1. Set the heating block to 95°C 
2. Prepare a working solution of sample buffer by addition of 850 µl Laemmli buffer to   
150 µl β-mercaptoethanol (prepare in fume cabinet), vortex thoroughly 
3. Calculate the appropriate concentration of each sample (e.g. 20 µg per sample), and 
calculate the number of samples needed 
4. Label microcentrifuge tubes for each sample and sample set 
5. Add a volume of working sample buffer  equivalent to 1/3 of total sample volume (2/3 
protein +1/3 sample buffer) 
6. Add appropriate volume of protein to each tube and punch holes in lid of each tube 
7. Heat samples in a  95°C heating block for 5 min 
8. Centrifuge each tube briefly for approximately 10 seconds and place on ice 
9. Samples can now be loaded on  SDS-PAGE gels or stored at – 20°C 
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Western blot buffers 
     Blocking buffer                                        Constituents 
      1% w/v BSA                           1 g BSA in 100 ml 1x TBS-T 
      5% non-fat milk                             5 g non-fat milk powder in 100 ml  
                                                              1x TBS-T       
* Blocking buffer dependent on the specifications of the specific antibody 
SDS-PAGE  
1. Clean spacer plates and short plates, casting frames, stands and rubber gaskets 
2. Place gasket in groves at the base of the stand and assemble glass plates in green frames with   
    the short plate facing the front. Make sure to tighten the clips to secure the plates. 
3. Place the assembled plates onto the rubber gasket in the base of the casting frame and securing  
    it with a clip. 
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4. Add dH2O between plates to check for leakage. 
5. Get two small beakers for the resolving and stacking gels 
6. Gels were make up using TGX™ and TGX stain-free FastCast acrylamide kit (Bio-Rad, 
Hercules CA) according to the following table:  
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                                                        Stacker            Resolver 
Resolver A                                               -                   3 ml x n      
Resolver B                                               -                   3 ml x n 
Stacker A                                            1 ml x n   - 
Stacker B    1 ml x n   - 
TEMED                                               2 µl x n             3 µl x n 
10% APS    10 µl x n            30 µl x n 
 
 
7. The resolving acrylamide gel solution was prepared by combining equal volumes of   
    resolver A and B solutions. 
8. Add the required volume of TEMED and freshly made 10% APS to the combined resolver A   
    and B solution and mix well. 
9. Carefully pipette the resolving gel solution into the glass plates using a Pasteur pipette – be 
sure to avoid introducing bubbles. 
10. Prepare the stacking acrylamide gel solution by combining equal volumes of stacker A and B  
     solutions.  
11. Add the required volume of TEMED and freshly made 10% APS to the combined  
     solution and mix well. 
12. Pipette the stacking gel solution into the glass plates using a Pasteur pipette. 
13. Insert the gel combs – be sure to avoid introducing bubbles. 
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14. Allow the gel to set for 30 – 45 min. 
15. Load molecular weight protein marker and protein samples. 
16. Gels were electrophoresed at 100 V (constant) and 400 mA until the protein marker reached  
      the bottom of the gel. 
 
Electrotransfer  
 Proteins were transferred onto the membrane using trans-blot
®
 turbo midi PVDF transfer packs  
 (Bio-Rad, Hercules CA) in the following manner:  
1. Place the membrane and the bottom stack on the cassette base. Make sure to use a blot roller  
    to remove any air bubbles- The anode stack and membrane are located at the bottom. 
2. Place 2 mini gels onto the membrane and gently use a blot roller to remove any air bubbles. 
3. Place the second wetted transfer stack on top of the gel. This will serve as a top ion stack. Be  
    sure to remove any air bubbles.  
4. Close and lock the cassette lid and insert the cassette into the Trans-Blot Turbo System
® 
    
 (Bio-Rad, Hercules CA). 
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Appendix I 
 
Respresentative Western blot images used as a loading control 
   
 
 
 
  
 
  
 
 
 
PDH 
ND AHF     ND AHF 
 + 1 µM TMZ 
AHF Diabetic   AHF Diabetic 
+ 1 µM TMZ 
3-KAT 
ND AHF     ND AHF 
 + 1 µM TMZ 
AHF Diabetic   AHF Diabetic 
+ 1 µM TMZ 
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ND AHF     ND AHF 
 + 1 µM TMZ 
AHF Diabetic AHF Diabetic 
+ 1 µM TMZ 
        UCP2 
SOD2 
ND AHF      ND AHF 
 + 1 µM TMZ 
AHF Diabetic   AHF Diabetic 
+ 1 µM TMZ 
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Appendix J 
Oxygen Radical Absorbance Capacity Solutions 
Tube Standard 
concentration (µM) 
Trolox stock solution 
(µl) 
Phosphate Buffer 
(µl) 
A 0 0 750 
B 83 125 625 
C 167 250 500 
D 250 375 375 
E 333 500 250 
F 417 625 125 
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Phosphate buffer (75 mM, pH 7.4) 
Solution 1: Weigh 1.035 g sodium di-hydrogen orthophosphate-1-hydrate in 100 ml beaker with 
the addition of 100 ml dH2O until dissolved. Solution 2: Weigh 1.335 g di-sodium hydrogen 
orthophosphate dehydrate in 100 ml beaker with the addition of 100 ml dH2O. Mix 18 ml of 
solution 1 with 82 ml of solution 2. Solution stored at 4 °C until needed. 
Trolox (control) (250 µM stock): 
Weigh 0.00312 g 6-Hydroxy-2 5,7,8-tetra-methylchroman-2carboxylic acid in 50 centrifuge tube 
and add 50 ml phosphate buffer until dissolved. This solution should yield an absorbance of 
0.670 ± 0.015 at 289 nm. 
Trolox standard (500 µM stock): 
Weigh 0.00625 g 6-Hydroxy-2 5,7,8-tetra-methylchroman-2carboxylic acid and add 50 ml 
phosphate buffer until dissolved. This solution should yield an absorbance of 0.670 ± 0.015 at 
289 nm. 
Fluorescein sodium salt: 
Dissolve 0.0225 g fluorescein sodium salt in 50 ml phosphate buffer. Store in dark container at   
4 °C 
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Peroxyl radical: 
Weigh 0.150 g 2,2’-Azobis (2-mthylpropionamidine) dihydrochloride (25 mg/L) into a 15 ml 
centrifuge tube. This solution should be prepared fresh. 
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